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Zusammenfassung 
Brustkrebs, genannt Mammakarzinom, ist eine maligne Veränderung des epithelialen 
Brustgewebes und repräsentiert eine der bösartigsten und häufigsten Form von Krebs bei 
Frauen. 
Ein signifikanter Teil aller Mammakarzinome weisen eine Überexpression des Humanen 
Epidermalen Wachstums Faktor Rezeptor-Moleküls HER-2 auf, welches mit aggressivem 
Krankheitsverlauf und einer ungünstigen Prognose assoziiert ist. HER-2 ist auf der 
Oberfläche von 30% der Krebszellen bei invasivem Brustkrebs, 70% bei duktalem 
Carzinoma in situ, aber auch bei Ovarial-, Nieren- und Dickdarmkarzinom überexprimiert.  
HER-2 Expression ermöglicht eine zielgerichtete Behandlung („targeted therapy“) mit dem 
humanisierten monoklonalen Antikörper Trastuzumab (Herceptin
®
) der gegen den 
extrazellulären Teil des Moleküls gerichtet ist. Probleme, wie ungleichmäßige Verteilung 
im Gewebe und limitierte Halbwertzeit von IgG Antikörpern und nicht zuletzt hohe Kosten 
vermindern jedoch die Attraktivität der sonst erfolgreichen passiven Immuntherapie. 
Daher wäre eine ebenso Epitop-spezifische, aber aktive Immuntherapie eine 
interessantere Alternative. Nach dem Prinzip von Impfungen gegen 
Infektionserkrankungen wird weltweit auch an „Impfung gegen Krebs“ gearbeitet. Die 
durch eine Impfung verstärkte Immunantwort gegen die körpereigenen Tumorantigene 
wäre besonders hilfreich, um einen Schutz vor Wiederkehren des Tumors oder 
Metastasierung, beispielsweise im Stadium der minimalen Resterkrankung („minimal 
residual disease“) zu verhindern. 
Mittels Phage-Display Technologie können Mimotope gegen wichtige Tumorantigene 
generiert werden. Mimotope sind kleine Peptide mit ähnlichen Eigenschaften wie die 
natürlichen Epitope auf einem Antigen. Mimotope können synthetisch hergestellt und an 
Carrier-Moleküle gekoppelt werden. Ziel dieser Studie war es, AAVLP (Adeno-Associated 
Virus-Like Particle) als völlig neuartige Mimotopcarrier auf ihre antigene und immunogene 
Eigenschaften zu testen und weiters sollte der mögliche inhibierende Effekt eines solchen 
AAVLP-Mimotope-Vakzines auf das Tumorwachstum getestet werden. AAV (Adeno-
assoziierter Virus) ist ein nicht humanpathogener, replikationsdefekter ssDNA Virus, der 
aus 60 Kopien dreier ähnlicher Kapsidproteine besteht. Wenn Fusionsmoleküle aus 
Mimotop und einen AAV Kapsidprotein exprimiert werden, können diese zu Virus-like 
particle, AAVLPs assembliert werden. Fertige AAVLPs präsentieren das Mimotop 60-mal 
auf der Partikeloberfläche.  
In dieser Studie wurden zuerst Immunogenität, Spezifität und die Sicherheitsaspekte 
einer AAVLP Impfung anhand des Modellallergens Ovalbumin evaluiert. Im zweiten 
Schritt wurde der anti – Tumoreffekt einer spezifischen HER-2 Mimotop Vakzine, vorerst 
in AAV Formal, in einem Tumortransplantmodell in BALB/c Mäusen getestet. 
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Abstract 
Breast cancer, alternately termed mamma carcinoma, is a malignant neoplasm 
deriving from mammary epithelial tissue, and represents one of the most malignant 
and common forms of cancer in females.   
In a significant number of all mammary carcinomas the Human Epidermal growth 
factor Receptor molecule HER-2 is overexpressed, being associated with aggressive 
disease course and bad prognosis. HER-2 is expressed on the surface of 30% of 
invasive breast cancer, in 70% of ductal carcinoma in situ, but also in carcinomas of 
the ovary, the kidney and the colon. Expression enables targeted therapy with the 
humanized monoclonal antibody trastuzumab (Herceptin®) that is directed against the 
extracellular part of HER-2. Problems like inhomogeneous distribution in tissue, 
limited half-life and last but not least high costs decrease attractiveness of elsewise 
successful passive immunotherapy with IgG antibodies. For these reasons, equally 
epitope-specific, but active immunotherapy would be an attractive alternative. 
According to the principle of vaccination against infectious diseases, worldwide efforts 
are undertaken to develop anti-cancer vaccines. By vaccines immune responses 
against (self-) tumor-antigens could be achieved to protect against tumors or 
metastasis recurring during minimal residual diseases. 
Using phage-display technology, mimotopes against important tumor antigens can be 
generated. Mimotopes are small peptides harboring similar biological and 
physicochemical properties like the natural epitopes. Mimotopes can be produced 
synthetically and coupled to carrier molecules. The aim of this study was to test the 
antigenic and immunogenic properties of AAVLPs (adeno-associated virus-like 
particles) as novel mimotope carriers. Furthermore the potential inhibitory effects of 
an AAVLP tumor vaccine against tumor growth should be tested. 
AAV (adeno-associated virus) is a non-human pathogenic, replication defective 
ssDNA virus, consisting of 60 copies of three similar capsid proteins. Fusion proteins 
of mimotope and a capsid protein can be assembled as virus-like particles, AAVLPs. 
AAVLPs present the mimotope 60 times on the particle surface in a high density 
display fashion. 
In this study first the immunogenicity, specificity and safety aspects of an AAVLP 
mimotope vaccine was evaluated using an ovalbumin B-cell epitope as a model 
antigen. Next, the specific anti – tumor effect induced by an HER-2 mimotope vaccine 
in AAV formal was tested in a BALB/c tumor transplant mouse model.   
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1 Introduction 
1.1 Cancer 
The immune system is responsible for keeping body homeostasis by protection 
against invading pathogens and by elimination of self- cells, which are suspicious due 
to modified surface, characteristics and growth. Tumor cells break basic rules of cell 
behavior, as they show uncontrolled growth by increased cell division rate, often 
accompanied by decreased apoptosis besides other aberrant characteristics.  
Together, this gives rise to a neoplasm, which in the beginning is benign, as long as 
the basal lamina stays intact and therefore does not infiltrate other tissues or the 
vascular system. A neoplasm in that stage has a better prognosis than a tumor, 
having penetrated the basal lamina. Local destructive growth and/or invasiveness are 
the main characteristics of cancer. When the basal lamina is destroyed, the malignant 
cells may invade surrounding tissues and penetrate blood and lymphatic vessels. 
Disseminated tumor cells may form secondary tumors called metastases, which may 
severely harm also distant organ functions of the cancer patient, illustrated in figure 
1.1. 
 
 
Figure 1.1:  Way of metastasis from Alberts et al. [1]. 
 
Tumors can be classified according to their original cell type or tissue location, e.g. a 
tumor originating from connective tissue or from muscle cells is defined as sarcoma. 
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A tumor with epithelial origin is called carcinoma, which is the most common form of 
cancer in humans. About 80% of tumors are originating from epithelial tissue, which is 
often related to a) exposure of internal or external body surfaces to physical or 
chemical environmental stress causing genotoxic events, and b) intrinsically higher 
proliferation rate reducing the time for successful DNA-repair, and a risk to amplify 
mutated cells. 
Tumors are further classified according to the benignity or malignity. For instance an 
adenoma is a benign epithelial tumor with glandular organization, whereas 
adenocarcinoma is its malign form. There are many other categories of tumors like 
leukemia, lymphoma, glioblastoma, etc. depending on the cell type and origin [1]. 
In figure 1.2 worldwide cancer incidence and mortality of the year 2008 is illustrated. 
The most frequently occurring tumors in both sexes are found in the reproductive 
tract, in the respiratory system and in digestive organs. Breast cancer is the leading 
type of tumors in the female population worldwide [2]. 
 
 
Figure 1.2: GLOBOCAN worldwide cancer incidence and mortality in women and men [2]. 
 
1.2 Breast cancer 
Breast cancer is a malignant neoplasm originating from breast tissue, called 
mammary carcinoma and is one of the most malignant and common forms of female 
cancer [3].   
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 Epidemiology: Mortality and Morbidity 1.2.1
The lifetime risk for mammary carcinoma in females is up to one tenth. Mammary 
carcinoma comprises 16% of all female tumors and about 11% of all breast cancer 
patients are young women at the age below 35 [3,4]. In western societies breast 
cancer shows the highest incidence rates which has been correlated to modern life 
style, as outlined below. Incidence is lower in less-developed countries due to higher 
rates of infectious diseases possibly triggering immune responses and lower overall 
expectancy of life [5].  
According to the GLOBOCAN World Cancer Report of the year 2008, breast cancer 
was the cause of 458.503 deaths worldwide, comprising about 13.7% of all female 
cancer deaths [2]. Mammary carcinoma is 100 times more common in women than in 
men, although males tend to have poorer outcomes due to delayed diagnosis [6].  
 
 Physiology and Pathology 1.2.2
 Anatomy and Physiology 1.2.2.1
The female breast, also called mamma (lat.) consists mainly of the mammary gland, 
as well as adipose and connective tissue, anatomically located on the muscle 
musculus pectoralis major. The mammary gland consists of 10 to 20 smaller single 
glands called Lobi with one major ductus lactifer colligens, ending in the sinus lactifer 
located in the mamilla, responsible for secreting milk. Blood supply is performed 
mainly by the internal mammary artery and venous drainage by the axillary vein. 
Anatomy of the female breast is illustrated in Figure 1.3 [7]. 
 
 
 
1 thorax 
2 musculus pectoralis major 
3 lobi 
4 mamilla 
5 areola 
6 ductus lactifer colligens 
7 adipose tissue 
8 skin 
 
 
 
Figure 1.3: Anatomy of female breast [8]. 
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 Pathology 1.2.2.2
Tumors may often be etiologically related to previous inflammations of the mamma, 
defined as mastitis. Mastitis often is very painful and of bacterial or viral origin 
resulting during breast-feeding. 
Fibrous cystic mastopathia is a proliferation of connective tissue forming cysts 
followed by nodular lesions. In some cases epithelia start to proliferate very quickly 
and atypically, which may be an indication for tumor initiation. 
A fibroadenoma is a benign neoplasm, very robust and compact with a clear 
borderline, originating from proliferation of connective tissue and glands, often 
diagnosed in young women aged around 20. Other benign tumors of the mamma are 
intraductal papillomas and phylloid tumors [9].  
Breast cancer malignancies can be classified in different ways. According to the 
histopathology most breast malignancies arise from epithelia of a duct or a lobule, 
consequently called ductal or lobular carcinoma. If the basal membrane is still intact 
and the tumor has not yet infiltrated other tissues, tumors are described as lobular 
carcinoma in situ (LCIS) or as ductal carcinoma in situ (DCIS). According to 
Nottingham Modification of the Bloom-Richardson grading another indication is that 
surrounding tissue is still untouched and tumor progression is of low grade. This 
grading system categorizes tumor cells according to their differentiation, meaning 
their tubule formation, nuclear pleomorphism and their mitotic counts. Well-
differentiated cells are classified as low grade (grade 1), intermediate differentiated as 
grade 2, poorly differentiated (or high grade) cells as grade 3 and undifferentiated, 
finally the highest grade (grade 4) is associated with poorest prognosis [9]. 
 
The TNM classification of malignant tumors has been developed by the Union for 
International Cancer Control (UICC) and the American Joint Committee on Cancer 
Staging (AJCC). T stands for the size of the Tumor, N defines whether regional lymph 
Nodes are affected, and M describes whether a tumor has already Metastasized. 
Together, T, N and M are used for tumor staging I to IV. Stage 0 is defined as pre-
cancerous condition, i.e. tumor in situ (Tis) either a DCIS or a LCIS; stage I to III 
means cancer without metastasis and relatively good prognosis and stage IV 
classifies advanced metastatic carcinoma with poor prognosis (table 1.1) [10].  
 
T (CIS, 0–4): T0: no primary tumor 
   T1: primary tumor smaller than 2cm 
   T2: primary tumor 2 – 5cm 
   T3: primary tumor bigger than 5cm 
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N (0–3):  N0: no tumor cells in regional lymph nodes 
N1: metastasis present in regional lymph node  
N2: tumor spread between N1 and N3  
N3: tumor cells in distant or numerous regional lymph nodes 
M (0/1):  M0: no distant metastasis 
M1: metastasis in distant organs (beyond regional lymph nodes) 
 
 
 Etiology of breast cancer 1.2.3
Different risk factors that induce tumor initiation could be identified, like age and sex 
[4,6]. Especially high levels of estrogen play a major role in breast cancer etiology, 
like early menarche, late or lack of childbearing or breastfeeding and late menopause 
[11]. More recently, also contraceptives and hormone replacement during menopause 
were discussed as possible factors. Higher incidence in the western world, like North 
America, Western and Northern Europe and Australia correlates with higher income 
and modern lifestyle, associated with high alcohol consumption, tobacco smoking, 
high fat diet and obesity. All of these aspects have been associated with the risk of 
tumor formation in the female breast, compared to much lower incidence values in 
lower family income countries [12-14].  
 
Moreover, breast cancer can be the result of genotoxic events. DNA damages caused 
by UV-radiation or other environmental factors are usually corrected by special DNA 
repair programs. These DNA repair mechanisms can be overwhelmed when the 
number of genotoxic events increase. Mutations are especially critical when occurring 
in gene loci coding for tumor suppressor proteins or proto-oncogenes. Mutation in 
Table 1.1: TNM staging for breast cancer [10]. 
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these genes can result in loss-of-function of proteins having significant regulatory 
functional on cell growth and often may lead to carcinogenesis. One of the most 
common mutations associated with breast cancer is observed in the gene BRCA1 
(breast cancer antigen 1) that is mainly responsible for DNA repair of double strand 
breaks. The gene BRCA1 is located on the long arm of chromosome 17 at band 21 
and a loss-of-function of this protein increases the risk for breast cancer as part of the 
hereditary breast-ovarian cancer syndrome [15]. Similar effects result from BRCA2, 
located on the long arm of chromosome 13 at position 12.3, which also interacts in 
DNA repair of double strand breaks [16]. It could also be demonstrated that 5 to 10% 
of all breast cancers are hereditary; 80 to 90% of those are caused by mutations in 
the genes BRCA1 or BRCA2 [17]. 
 
 Diagnosis 1.2.4
Early symptoms, like suspicious nodes should be taken seriously, although luckily in 
many cases they turn out to be unrelated to breast cancer. Also atypical locations, like 
a node beneath the breast, in the axilla or in supraclavicular areas can be hints for 
breast cancer, as well as pain, ulceration, skin dimpling, skin discoloring, edema, 
erythema or inversion of the mamilla. For screening purposes, mammograms should 
be carried out every second year after the age of 40 and even more often in high-risk 
families. Nodes, calcifications or other pathologic alterations can be detected by a 
mammogram and are an indication for further diagnostic procedures, like histological 
and cytological core biopsies or abdominal sonographies [18,19].   
For choosing the right treatment and prediction of prognosis, definition of the receptor 
status on the surface of tumor cells is essential. There are three major tumor 
associated antigens that can be expressed on the surface of mammary carcinoma 
cells: estrogen receptor (ER), progesterone receptor (PR) and human epidermal 
growth factor receptor 2 (HER-2). ER and PR can be stimulated by the respective 
hormones with positive effects on tumor growth. These tumors are often associated 
with relatively better prognosis. HER-2 expression, however, correlates with bad 
prognosis. The present Master thesis concentrates on this important molecule. Tumor 
cells with none of these receptors expressed on their surface are defined as basal-like 
or triple negative [20].  
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 Human Epidermal growth factor Receptor 2 1.2.5
The Human Epidermal growth factor Receptor 2 (HER-2, HER-2/neu, ErbB-2, c-erbB-
2, p185HER-2) is a 185kDa protein [21]. The HER-2 proto-oncogene is located on 
chromosome 17q21 and encodes 1255 amino acids forming the transmembrane 
glycoprotein p185HER-2 or simplified the HER-2. HER-2 belongs to the family of 
epidermal growth factor receptors (EGFR family). As the other family members, HER-
1 (ErbB-1), HER-3 (ERbB-3) and HER-4 (ErbB-4), HER-2 is a transmembrane 
tyrosine kinase receptor. All except HER-3 harbor functional intracellular tyrosine 
kinase domains and a transmembranous lipophilic segment. All members of the 
EGFR family, except HER-2, additionally possess an extracellular ligand-binding 
domain [22]. 
 
 
Figure 1.4: Ligands binding to HER family members [23]. 
 
As illustrated in figure 1.4, selected ligands that trigger the EGFR family members are 
the epidermal growth factor (EGF), transforming growth factor - α (TGF-α), 
amphiregulin (AR), heparin-binding EGF (HB-EGF), neurigulins (NRG), epiregulin 
(EPR). The single EGFR family members must dimerize to become activated. They 
form either heterodimers or homodimers which activate by cross-phosphorylation the 
Ras-MAP-Kinase signaling pathway or the PI3-Kinase signaling machinery, 
consequently stimulating cell proliferation, cell survival, cell mobility and 
neoangiogenesis via VEGF release (figure 1.5). However HER-2 is the preferred 
signaling partner chosen by all other isoforms [22-24]. 
 
To shut off signaling EGFR complexes are internalized via clathrin-coated pits and 
transported to the endosome, where ligands are removed and degraded and free 
receptors can be shuttled back to the cell membrane. Moreover, the receptors can be 
degraded as well, whereby the adaptor protein Cbl, an ubiquitin ligase, plays a 
prominent role.  
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Also anti-HER2 antibodies induce degradation and thus down regulation of HER-2 by 
recruiting Cbl [23,24]. 
 
 
 
Figure 1.5: EGFR family members and signaling [22]. 
 
In physiological condition HER-2 and the other EGFR family members play a 
prominent role in the development of the human fetus, especially of the nervous 
system, developing of bone, muscle, skin, heart, lungs and intestinal epithelium. In 
contrast, only low levels of these proteins are expressed in mature tissue. In settings 
of HER-2 overexpression growth signaling cannot be shut off, meaning enhanced cell 
multiplication and survival causing malignant growth and tumor formation. 
Furthermore, degradation of the receptor is impaired, leading to recycling back to the 
plasma membrane, making them available for a new signal stimulus. The monoclonal 
antibody trastuzumab (Herceptin®), targeting HER-2, interferes in this potent and 
aggressive mechanism, which will be discussed below. Consequently, reduced 
numbers of HER-2 molecules are no longer available to form heterodimers with other 
HER family members, thus minimizing signaling and alleviating tumor growth [22-24].  
 
 Therapies against breast cancer 1.2.6
According to the stage of disease, different therapy options are available including 
combinations of surgery, chemotherapy, anti-hormone treatments or irradiation [18]. 
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Localization of the tumor, inflammation, whether there is a clear borderline between 
tumor and breast, and the age of the patient are important factors to decide if only a 
part or the whole breast will be removed. Today, the overall aim is to operate breast-
conservingly, especially in young patients. Nevertheless it is important to remove 
tumor tissue along with surrounding healthy tissue and to check for proximate lymph 
nodes in the axilla, especially the sentinel lymph node, which is the first draining 
lymph node of the tumor region. Hence cryosections from breast tissue and lymph 
nodes are taken during the surgical intervention and checked for affection [25]. 
 
Often after surgery radiotherapy is used to destroy remnants of tumor cells that could 
not be removed surgically and may proliferate or invade damaged tissue caused by 
surgical wounding. Furthermore it alters the tumor microenvironment making it less 
favorable for tumor cell growth and invasion. Radiotherapy can additionally be given 
intra-operatively, which results in relatively higher tumoricidal effects than 
conventional whole-breast radiotherapy [26]. 
 
Hormone blocking therapies are applied in hormone receptor positive breast cancer, 
e.g. ER positive. Estrogen is a growth stimulus for tumor proliferation and can either 
be treated by inhibition of the hormone receptor, or with drugs that block the effects 
induced by the hormone. Alternate hormone therapy agents are aromatase inhibitors 
which inhibit the production of estrogen in women [27]. 
 
The mechanism of chemotherapy most often applied intravenously is to destroy fast 
growing cells, which replicate more often, a main characteristic of many cancer cells. 
Another mechanism is induction of DNA damage resulting in cell death. The main 
problem of chemotherapeutics is their high systemic toxicity, meaning that they 
unspecifically kill dividing cells, including cells in bone marrow, the digestive tract and 
hair follicles, resulting in massive side effects. The most commonly used 
chemotherapeutics are Cyclophosphamid, Epidoxorubicin and 5-Fluorouracil (CEF-
scheme). This combination especially bears a high risk of cardiotoxicity [28]. 
 
All these above mentioned therapy options for cancer treatment produce either local 
or systemic serious side effects, which can be avoided with targeted therapy, for 
instance by using monoclonal antibodies. These antibodies are derived from a 
specific B-lymphocyte clone detecting one specific epitope. In contrast, polyclonal 
antibodies are derived from different B-cell clones recognizing each a different 
epitope of a specific antigen [29]. 
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 Trastzuzmab (Herceptin®) 1.2.7
The most prominent monoclonal antibody with clinical activity against HER-2 
overexpressing mammary carcinoma cells is trastuzumab (Herceptin®). The U.S. 
Food and Drug administration (FDA) approved it for passive immunotherapy for 
metastatic breast cancer in the year 1998. Trastuzumab is the basis for all our 
immunotherapeutical approaches against cancer [30]. Figure 1.6 illustrates the 
antibody – HER-2 complex. 
 
A 
 
B 
 
 
Figure 1.6: A) 3D-model based on co-crysalization of trastuzumab binding to HER-2. 
The different domains of HER-2 are colored in blue (domain I), green (domain II), yellow 
(domain III) and the domain IV in red. Purple and gold show disulphide bonds of the 
molecules. Herceptin is colored in turquoise binding to the domain IV [31]. 
B) Detailled molecular analysis of the trastuzumab epitope on HER-2. 
The figure shows the exact attachment of trastuzumab to sHER-2. Herceptin
®
 is again colored 
in turquoise and the backbone domain IV of HER-2 in red. Yellow demonstrates the side 
chains of residues contacting the Fab region of the humanized antibody. The N and C termini 
of the displayed HER-2 region are indicated as three loop regions, loop 1 (residues 557–561), 
loop 2 (residues 570–573) and loop 3 (residues 593–603), which are in contact to the 
Herceptin Fab fragment. Red dots indicate an eight-residue loop not directly visible in the 
structure [31].  
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Trastuzumab is a humanized antibody, being constructed of human variable region 
framework residues and an IgG1 constant domain, but still containing the antigen 
binding loops from the original mouse monoclonal antibody 4D5 [32].  
There are several described mechanisms of action of this antibody, illustrated in 
figure 1.7. One way is that trastuzumab binds a juxtamembrane domain of the 
extracellular part of HER-2 to prevent signaling induced by the membrane-bound-
phosphorylated protein p95, a HER-2 fragment emerging from cleaving (C). 
Furthermore, trastuzumab can block either homo- or heterodimerization of HER-2 
with other members of the EGFR family, which favors dimerization of the other HER 
members resulting in minimization of the tumor promoting signals (D). Trastuzumab 
may interact via its Fcγ domain with FcγR positive effector cells, such as NK cells and 
induce antibody-dependent cell-mediated cytotoxicity (ADCC) (E). Finally, 
trastuzumab induces vesicular endocytosis resulting in HER-2 degradation leading to 
receptor down-regulation and making the cancer cells less susceptible to growth 
stimuli (F).  
To sum up, trastuzumab binds HER-2 and thereby inhibits its signaling cascade, 
resulting in inhibition of tumor growth, proliferation, lower cell survival and inhibition of 
invasiveness [22,30].  
 
 
Figure 1.7: Herceptin
®
 activity mechanism [22]. 
 
Trastuzumab can be used alone or as an adjuvant to almost all conventional 
chemotherapies for treatment of HER-2 overexpressing breast cancers being above 
2+ or 3+ using the HercepTest® in immunohistochemistry or the FISH (Fluorescence 
In Situ Hybridization) technology. According to a patient’s indication, contraindication 
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and coexisting conditions, a loading dose of 4-8mg, followed by 6mg per kg body 
weight every third week is recommended. The advantage of this targeted therapy is to 
circumvent or reduce classical side effects caused by other anti-tumor treatments. 
Nevertheless there are still adverse reactions against the passively applied 
monoclonal antibody in some patients, like cardio toxic effects or acute 
hypersensitivity reactions, but lower amounts than 10% [21,22]. 
Other critical limitations of monoclonal antibody therapy are their limited half-life, 
prolonged application time, irregular distribution in tissue and the immense production 
costs to achieve sufficient antibody titers for anti-tumor activity. All these factors 
decrease attractiveness of the otherwise so successful passive immunotherapy. 
Therefore an active immunotherapy rendering antibodies of similar specificities like 
trastuzumab would be an interesting and promising treatment alternative, with the 
advantage of a continuously available polyclonal immune response, taking advantage 
of effector mechanisms of several immunoglobulin isotypes [33-35]. 
 
1.3 Mimotopes 
Mimotopes are small epitope-mimicking structures, varying from 6 to 20 amino acids 
in length. Mimotopes thus harbor equivalent structural, biological and 
physicochemical properties and only sometimes a similar sequence as their natural 
epitope on an antigen. Yet sequence homology alone is not enough to resemble a 
conformational B-cell epitope and therefore, is not really necessary. Mimotopes very 
closely, but not completely, resemble the 3D-structure of the original epitope, with its 
biochemical and electrostatic properties. When used for immunization, mimotopes 
induce similar antibody specificities as the natural antigen epitopes, due to the 
principle of molecular mimicry. 
 
This mechanism can be exploited in anti-cancer therapy. When tumor cells 
overexpress tumor-associated antigens (TAA), e.g. growth factor receptors or 
glycoproteins, they are by nature well-tolerated self-molecules of low antigenicity. Via 
the mimotope technology it is possible to generate epitope mimics which are similar, 
but not identical to the TAA. These TAA mimotopes are therefore suitable to break 
tolerance and to induce a B-cell epitope-specific humoral immune response with 
memory function. Antibodies produced by mimotope vaccination are therefore not 
only directed against the immunogen, but also towards the natural epitope expressed 
on the tumor cell. This polyclonal antibody response composed of different 
immunoglobulin isotypes with various effector functions can consequently stimulate 
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ADCC, complement-dependent cytotoxicity (CDC) and other effects resulting in 
cancer cell death, depicted in figure 1.8 [35,36]. 
  
 
Figure 1.8: Mimotope vaccines: Epitope mimics induce anti-cancer antibodies. Due to 
molecular mimicry, mimotope vaccines induce a polyclonal immune response not only directed 
against the mimotope, but also against the natural tumor-associated antigen. These antibodies 
are able to mediate cytotoxicity in cancer cells, like ADCC or CDC [36].  
 
Antibodies can be tumor-inhibitory or tumor-promoting due to their epitope specificity. 
The latter would eventually even enhance malignant growth (figure 1.9). Thus the 
definition of the epitope-specific biological function of antibodies and the definition of 
the exact molecular binding site is of fundamental importance. Hence, the 
identification of reactive centers, ligand-binding grooves, as well as crystallization 
experiments of TAAs are of considerable importance for the directed induction of 
growth inhibitory immune responses [33,37].  
 
A      B 
 
 
 
 
 
 
 
 
Inhibitory IgGs 
Figure 1.9: Promoting (A) and inhibitory (B) antibodies. Heterodimerization of HER family 
members induced by IgG antibodies promotes strong signaling in cancers (A); in contrast, 
inhibitory IgGs block heterodimerization resulting in down regulation of tumor promoting 
signals (B) [35]. 
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Having determined mimotopes for the natural epitope, synthetic peptides can easily 
be produced. They are chemically stable, cost-effective and do not contain any 
infectious, toxic or oncogenic materials. However, due to their small size they are 
haptens only and non-immunogenic. To act as complete antigens and immunogens 
they have to be bound to a carrier molecule. Then, they can induce tumor-targeting 
antibodies. This could be demonstrated in a previous study for HER-2 mimotopes by 
our group. In this approach, we generated mimotopes by using the monoclonal 
antibody trastuzumab for screening a phage display peptide library [34]. 
 
 Phage display technology 1.3.1
Phage display library screening as a technology for generating mimotopes was first 
described in 1985 [35]. Phage libraries display about 109 or more different peptides. 
The colony repertoire is generated by cloning oligonucleotides into the genome of a 
phage, e.g. the filamentous bacteriophage fd using either minor (pIII) or major (pVIII) 
phage coat protein for surface display. Peptides can be presented in linear or in 
circular form, their length may vary between 6 to 38 amino acids in the different 
libraries.  
In the so called “biopanning” procedure, typically antigen specific antibodies are 
absorbed onto microtiter plates and incubated with the phage display peptide library. 
Antibodies will absorb then phages displaying peptides similar to the original epitope, 
whereas other phages are washed away during the following washing steps. 
Specifically bound phages are eluted by pH-change or by competition with the natural 
antigen and amplified for a next selection round. By several biopanning rounds, 
binding phage clones can be highly enriched. Subsequent colony screening methods 
identify the most specifically interacting phages, which are then cloned and 
sequenced. 
Selected mimotopes have to be stringently tested for specificity, mimicry and 
immunogenicity, illustrated in figure 1.10 [35].   
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Figure 1.10: In “biopanning”, specific mimotopes are selected by incubation with a monoclonal 
antibody. After several rounds to enrich the number of binding phages, mimotopes were tested 
for specificity, mimicry and immunogenicity [35]. 
 
 Mimotope carrier 1.3.2
As already mentioned above mimotopes have to be coupled to carriers before 
vaccination.  
KLH (keyhole limpet hemocyanin) is a typical carrier, being even FDA approved. It is 
a large multi subunit, oxygen-carrying glycosylated metalloprotein, derived from the 
hemolymph of the giant keyhole limpet. KLH elicits strong immune responses by 
offering additional T-helper epitopes for stimulating B-cells. Additionally KLH may 
activate cytotoxic T-cells (CTL) by inducing the production of interleukin IL-2 [35,38]. 
Another example of a system to achieve high antigenic density are MAPs (multiple 
antigenic peptides). Thereby, linear peptides are synthesized directly on a tyrosine 
backbone in tetrameric or octameric form. In studies with CEA (carcino embryonic 
antigen) - mimotopes an octameric “multiple antigen mimotope” (MAM), was 
successfully employed in preclinical anti-cancer vaccination studies [35,38].  
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Many different carrier technologies are currently in development, including viral and 
bacterial vectors (DNA vaccines), liposomes, ISCOMs (immune stimulating 
complexes, based on lipids), micro- and nanoparticles and others. However, 
virosomes and virus-like particles are regarded as the most promising technologies 
for vaccine antigen delivery today. Both, virosomes and VLPs make B-cell epitopes of 
interest highly immunogenic [39,40]. 
Considering the fact that vaccination originally was developed and employed most 
successfully in infectious diseases, also we hypothesized that virus particle might be 
attractive carrier systems for mimotopes. In this master thesis we propose Adeno-
associated viruses as an ideal carrier platform for B-cell epitopes, i.e. mimotopes. 
 
 Adeno-associated virus 1.3.3
Adeno – associated viruses (AAV) are nonenveloped small ssDNA viruses and 
belong to the Baltimore classification type II viruses, illustrated in figure 1.11. They 
are also members of the genus Dependoviruses from the family Parvoviridae. AAVs 
are replication defective, meaning that they are not able to replicate without a helper 
virus, which is in this case an Adenovirus (AV). Although AAVs are nonpathogenic to 
humans, they can infect dividing and non-dividing cells, and furthermore they are able 
to integrate latently into host DNA, resulting in seropositive individuals [41,42].  
 
A 
 
 B 
 
 
 
 
 
 
 
12 different primate serotypes (AAV1-12) exist with icosahedral symmetry. AAV2 
consists of 60 capsomers, each a quadrilateral 'kite-shaped' wedge, which allows the 
incorporation of a selected antigen or protein for display on the particle’s surface, as 
can be seen in figure 1.12. A protein of interest, an epitope or a mimotope can be 
Figure 1.11: Baltimore classification (A) and electron microscopy of AAV (B) [43]. 
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displayed thus 60 times on the surface of the capsomeres by modifying the gene 
sequence of the AAV.  
 
 
Figure 1.12: Atomic structure of adeno-associated virus (AAV2) [41]. 
 
AAVs enter cells via binding to heparan sulfate proteoglycan, the primary cellular 
receptor binding of this virus. Furthermore, co-receptors like fibroblast growth factor 
receptor-1, hepatocyte growth factor receptor and ανβ5 integrin are involved in the 
internalization program of AAV2. After docking for cell entry, viruses are taken up by 
receptor-mediated endocytosis through clathrin-coated pits and get transported to the 
nucleus by different possible pathways, depicted in figure 1.13. The virions are 
processed in the endosome. Consequently a phospholipase domain located on the 
capsid allows endosomal escape and nuclear targeting. In the nucleus uncoating is 
performed, releasing the viral genome for integration into the host cell genome or to 
form episomes [44-46]. 
 
 
Figure 1.13: rAAV2 cell entry and life cycle [44]. 
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 Adeno-associated virus like particles 1.3.4
Vaccination with viruses, although often in attenuated or inactivated form, elicits 
strong immune responses but may induce several side effects. These difficulties can 
be solved by recombinant techniques, which allow the production of simple viral 
structures or capsids lacking viral nucleic acid and therefore minimizing virus induced 
disadvantages [40,47].  
 
Adeno-associated virus-like particles (AAVLP) are generated synthetically via 
assembling of only one backbone capsid protein, which in this master thesis is VP3. A 
B-cell epitope of choice can be fused into appropriate insertion sites of VP3 in order to 
enable high-density presentation on the surface of assembled VLP [48]. By definition 
AAVLPs do not carry any DNA as they assembled without any genetic material. 
AAVLPs are of general viral size, but exact size and morphology depends on the 
nature of the epitopes, engineered into the VP3 fusion protein. The assembled VLP 
represents a more immunogenic tool than single subunits of proteins and stimulate 
the humoral as well cellular immune responses. Yet, VLPs do not induce an immune 
reaction as strong as conventional viral vaccines, immunization therefore requires 
frequent and larger doses in combination with a dominant adjuvant. Besides 
presentation of the chosen protein VLPs also mimic the structure of the native virus 
resulting in the formation of antibodies. Some VLPs via uptake by dendritic cells and 
presentation across MHC class II show self-adjuvant effects, meaning stimulation of 
the innate immune system. However, also CTLs can be activated by exogenous VLPs 
that were cross-presented by MHC class I molecules. Simultaneous activation of the 
innate and adaptive branches of the immune system is thus another advantage of 
VLP vaccines. In addition, they are a safe and effective approach for triggering 
antibody production against surface epitopes in cases where soluble forms of proteins 
fail to be sufficiently effective (figure 1.14) [49]. 
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Figure 1.14: Key facts of AAVLPs as vaccine display system [50]. 
 
 Adjuvants 1.3.5
Adjuvants are tools to enhance the immune responses toward vaccine antigens to 
induce high levels of antibodies and T-cell responses. Further they may modulate the 
resulting immune response and support memory function. Another advantage is that 
less antigen and fewer injections are needed when adjuvants are used due to depot 
effects. There are different adjuvants available (reviewed by our group in [51]) among 
which the most prominent were selected for experiments within this master thesis and 
are shortly discussed below:  
A) The adjuvant aluminum hydroxide (Alum) is the most widely used adjuvant. It 
absorbs antigens via electrostatic, hydrophobic attraction and ligand exchange. Alum 
enhances the efficacy and duration of antigen presentation by antigen presenting 
cells (APCs) by forming a depot at the site of injection and thus high and sustained 
local antigen concentration. Among APCs, activated macrophages adapt a dendritic 
cell-like phenotype that further stimulates T-cells, especially TH2 cells, releasing IL-4 
causing isotype switch towards IgG1 and IgE in mice. Although Alum is broadly and 
successfully used in a plethora of vaccines, including allergen immunotherapy, its 
usage might be a disadvantage in treatment of allergy due to further boost of TH2 
bias. Side effects may in rare cases be granuloma formation, abscesses, eosinophilia 
or myofasciitis, but overall aluminum hydroxide is regarded as safe and accordingly is 
also FDA approved [51]. 
B) The other adjuvant used exemplarily in this study is Montanide ISA adjuvant®, a 
water-in-oil emulsion based on a lipid formula. It consists of an enriched light mineral 
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oil extremely emulsified with mannitol and purified oleic acid of vegetable origin. 
Montanide favors humoral immunity without cell-mediated response. Adverse 
reactions may be abscesses and granuloma formation, which could be minimized by 
decreasing the amount of injection [52,53]. 
 
1.4 Allergy 
 Hypersensitivity reactions 1.4.1
Hypersensitivity or allergy defines a condition where adaptive immune responses are 
triggered against non-harmful environmental antigens, such as food, pollen or drugs. 
According to the Coombs and Gell classification, allergy can be classified into four 
types, type I to type IV (illustrated in figure 1.18). Type I hypersensitivities are 
immediate reactions mediated by IgE antibodies and are directed against soluble 
antigens, termed allergens. Upon exposure to an allergen susceptible individuals may 
get sensitized and form IgE, which immediately gets fixed to high affinity IgE 
receptors on inflammatory cells such as mast cells or basophile granulocytes. Upon 
subsequent allergen encounter, the allergen can then crosslink IgE on effector cells in 
diverse tissues, resulting in mediator release. The most important mediator is 
histamine, rendering vasodilatation and bronchoconstriction, leading to the clinical 
symptoms of e.g. asthma, allergic rhinitis or systemic anaphylaxis within minutes. 
Type II allergy reaction is mediated by IgG antibodies that bind to cell-surface or 
matrix-associated antigens recognized by phagocytes. Target cell destruction may 
then be initiated by immune complex mediated complement activation. Examples of 
this kind of hypersensitivity reaction are drug allergies or rhesus incompatibility, where 
a Rhesus negative mother (sensitized during a first pregnancy) gives birth to a 
second Rhesus positive child. Then maternal IgGs are directed against the rhesus 
antigen on fetal erythrocytes, which may lead to severe hemolysis (morbus 
heamolyticus neonatorum). 
In type III hypersensitivity, IgG antibodies are formed against soluble antigens 
rendering immune complexes additionally activating the complement system. These 
formed immune complexes precipitate, cause inflammation in e.g. endothelia, skin or 
intestine and are able to trigger tissue damage. The two major types of type III 
reaction are Arthus reaction and serum sickness. 
Type IV hypersensitivity reactions are T-cell mediated and delayed. They can be 
divided into three groups dependent on the involved T-cell type. TH1 cells cause upon 
antigen contact inflammatory response by macrophage activation, like for instance in 
contact dermatitis or the tuberculin reaction. TH2 cells are induced upon chronic 
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allergen encounter and activate predominantly eosinophils. Eosinophilic inflammation 
is typically seen in chronic asthma or chronic allergic rhinitis. The third form of type IV 
hypersensitivity depends on cytotoxic T-cells. This kind of inflammation is besides TH1 
cells seen in contact dermatitis [29]. 
 
 
Figure 1.15: Coombs and Gell classification of hypersensitivity [29]. 
 
 Ovalbumin as model antigen/ allergen 1.4.2
Ovalbumin (OVA) is the main component of a bird’s egg white, making up about 60 to 
65% of the total proteins in egg. It is a glycoprotein with relative molecular mass of 45 
kDa and it is built up of 385 amino acids. Ovalbumin belongs to the family of the 
serpins, but lacks serine protease inhibitor activity. The protein is a strong antigen and 
allergen in humans as well as in animals. Therefore it is often used as model 
antigen/allergen in immunology and allergology. In this master study a dominant B-
cell epitope of ovalbumin is used to test immunogenicity, specificity and safety 
aspects of the AAVLPs as novel epitope/mimotope carrier systems [54].  
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1.5 Aim of this study  
The overall goal of this study was to test the potential of AAVLPs and AAVs as new 
carriers for B-cell vaccines, namely epitopes or mimotopes.  
The first aim was to investigate immunogenicity, specificity, and especially in vitro and 
in vivo safety using a B-cell epitope of ovalbumin as model allergen, displayed by 
AAVLPs in an anaphylaxis mouse model.  
The second aim was to use AAVs as specific display system of mimotopes of the 
important tumor antigen HER-2. Again, antigenicity, specificity and immunogenicity 
should be investigated and finally therapeutic potential of the vaccine proven using a 
tumor mouse model. From these studies it was expected to get sufficient arguments 
for also transferring the HER-2 mimotope vaccine into an AAVLP formal. 
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2 Materials and Methods  
2.1 Materials 
AAVLP and AAV particles suspended in 40% iodixanol were provided by Medigene 
(Martinsried, Germany). The adjuvant aluminium hydroxide (alhydrogel-S Suspension 
1.3%, sterile) was purchased from Serva Electrophoresis (Heidelberg, Germany) and 
Montanide ISA 51 VG (sterile, endotoxin free) from Seppic (Cologne, Germany). 
Trastuzumab (Herceptin®) and Rituximab (MabThera®) were obtained from Roche 
(Vienna, Austria) and Cetuximab (Erbitux®) from Merck KGaA (Vienna, Austria). 
96-well flat-bottom plates were ordered from Nunc immunoplate (Roskilde, Denmark). 
Standard murine IgG1, IgG2a, IgG2b and IgE antibodies (BD Pharmingen, 
Schwechat, Austria) were used. Primary detection antibody rat-anti-mouse IgG1, 
IgG2a, IgG2b and IgE were purchased from Southern Biotech (Birmingham, 
Alabama, USA), and secondary detection antibody goat-anti-rat IgG-HRP from GE 
Healthcare (Freiburg, Germany). Direct HRP labelled goat-anti-mouse IgG was 
obtained from Abcam (Cambridge, UK). ABTS (2,2'-azino-bis 3-ethylbenzthiazoline-6-
sulphonic acid) was purchased from Sigma (Vienna, Austria) and TMB substrate 
Reagent Set for ELISA from BD Bioscience (Schwechat, Austria). 
RPMI 1640 media, IMDM media, αMEM media, DMEM/F12 media, FCS, L-glutamine, 
penicillin, streptomycin, G148 geneticin and sodium pyruvate were all from Gibco, 
(Lofer, Austria). Cell culture flasks, 75cm² with canted neck and filtered cap were 
used from Iwaki (Dublin, Ireland), and sterile 96-well round-bottom plates from Costar 
(New York, USA).  
Evans blue (Merck KGaA Darmstadt, Germany). Phl p 5 (grass pollen allergen) was 
obtained from Biomay (Vienna, Austria). Positive mast cell degranulation compound 
48/80 (40µg/mL) was purchased from Sigma (Vienna, Austria).  
70 µm nylon meshes were used from BD Biosciences, Schwechat, Austria and 
Lympholyte-M from Cedarlane, Burlington, Canada.  
Concavalin A was delivered from Sigma (Vienna, Austria).  
IL-5 cytokine ELISA kit was purchased from eBioscience (Vienna, Austria).  
Ni-NTA mini column Kit and Ni-NTA agarose beads were purchased from Qiagen 
(Hilden, Germany). Polyprep® Chromatography Columns were delivered from Bio-
Rad (Vienna, Austria). Amicon Ultra-15 Centrifugal Filter Units Regenerated Cellulose 
30.000 MWCO were obtained from Millipore GmbH (Vienna, Austria), Slide-A-Lyzer 
Dialysis Cassette 10.000 MWCO 3-5mL capacity and Pierce BCA (bicinchoninic acid) 
protein assay reagent both from Thermo Scientific (Fischer Scientific, Vienna, 
Austria). 
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EZ4U cell proliferation assay was used from Biomedica Group (Vienna, Austria). 
Protein G Sepharose 4 Fast Flow was obtained from Fischer Scientific (Vienna, 
Austria) and Illustra MicroSpin™ G-25 Columns from VWR International (Vienna, 
Austria). 
 
 Particles 2.1.1
AAVLPs and AAVs were constructed and provided by Medigene. Whereas for the 
safety study AAVLPs were provided, the HER-2 tumor mimotope experiment was less 
advanced and done using AAV-display. AAV clones termed DMD1, DMD2 etc. 
comprised different mimotope sequences which are not revealed in this diploma 
thesis. 
 
 
 
 
 
 
 
 
All particles were adjusted to equal concentrations and tested for specific antigenicity 
before further experiments. 
 
Figure 2.1: Composition of AAVs and AAVLP particles used in this master thesis. AAV capsid 
protein VP3 is a N-terminally shortened version of VP1 and VP2. Insertion site 587 is located in 
the C-terminal region. 
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AAVLP AAV 
AAVLP – OVA epitope  AAV – HER-2 mimotope 
OVA aa 323-339 HER-2 mimotope 
100µg/mL  1.6E + 13 particles/mL 100µg/mL  1.6E + 13 particles/mL 
AAVLP – TP18 VP3 – TTSN  wtAAV 
cholesterol ester transfer protein random control peptide w/o control peptide 
100µg/mL  1.6E + 12 particles/mL 100µg/mL  1.6E + 13 particles/mL 
 
 Mice 2.1.2
Eight weeks old female BALB/c mice were purchased from Charles River (Sulzfeld, 
Germany). All experiments were approved according to the European Community 
rules of animal care with the permission of the Austrian Ministry of Science (BMWF-
66.009/0003-II/3b/2011). 
 
 Cells 2.1.3
 D2F2 is a breast cancer cell line derived from BALB/c mice. The term D2F2-E2 
describes this cell line being transfected with human HER-2 (kindly provided by 
Prof. Wei-Zen Wei, California). 
 CT26 is a murine colon carcinoma cell line, termed TAUF1.1 in HER-2 
transfected state (kindly provided by Prof. Manuel Penichet, UCLA, California). 
D2F2, D2F2-E2, CT26 and TAUF1.1 – cells were cultured in IMDM media 
supplemented with 10% FCS, 4mM L-glutamine, penicillin (100U/mL), 
streptomycin (100µg/mL) and 50µg/mL geneticin G418. 
 Lec-HER-2 cells, lymphatic endothelial cells from chinese hamster transfected 
with HER-2 secrete recombinant (r)HER-2 into the supernatant and are a kind gift 
of Prof. Do Leaky from John Hopkins University. These cells were maintained in 
DMEM/F-12 media supplemented with 5% FCS, penicillin (100U/mL), 
streptomycin (100µg/mL) and 50µg/mL geneticin G418. 
 BT474 is a human breast cancer cell line overexpressing HER-2. When termed 
mBT474, the same cell line has been once passaged through in vivo culture in a 
SCID mouse, kindly provided by the group of Prof. Walter Berger, Cancer 
Research Instiute, Medical University of Vienna. The culture was performed in α-
MEM media supplemented with 10% FCS, 4mM L-glutamine, penicillin 
(100U/mL) and streptomycin (100µg/mL). 
 RBL-2H3 basophil cells were provided from Prof. Arnulf Hartl (Paracelsus 
University of Salzburg, Austria). Cells were cultured in RPMI 1640 media 
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supplemented with 10% FCS, 4mM L-glutamine, 2mM sodium pyruvate, 10mM 
HEPES, 100μM 2-mercaptoethanol, penicillin (100U/mL), and streptomycin 
(100µg/mL).  
 
2.2 Methods: AAVLP OVA experiment  
 Mouse immunization 2.2.1
BALB/c mice were immunized with AAVLPs, presenting an OVA epitope (AAVLP-
OVA), or the control TP18 epitope (derived from rabbit cholesterol ester transfer 
protein 18) (AAVLP-TP18). For positive control purposes mice were also immunized 
with the model allergen OVA (not coupled to AAVLP). By using either aluminum 
hydroxide (Alum) or Montanide ISA 51 VG® (Mont) as adjuvants, any effects on TH 
bias were tested. Altogether a volume of 200µL was given to each individual 
subcutaneously (s.c.). The detailed immunized protocol is shown in figure 2.2 and 
table 2.1. Mice were immunized three times with intervals of two weeks, on day 1, 14 
and 28. Blood samples were taken before starting the experiment (PIS – pre immune 
sera) and after each immunization (MIS – mouse immune sera) on days 13, 27 and 
41 for testing the immune response against the vaccine. 
 
 
Figure 2.2: AAVLP OVA immunization experiment. 
 
Groups Adjuvant  Mice/group 
A: Naïve     (n=4) 
B: OVA (7.2µg in 100µL PBS) + Alum (50µL) + PBS (50µL) (n=5) 
C: AAVLP-TP18 (100µL) + Alum (50µL) + PBS (50µL) (n=5) 
D: AAVLP-TP18 (100µL) + Mont (100µL)  (n=5) 
E: AAVLP-OVA (100µL) + Alum (50µL) + PBS (50µL) (n=5) 
F: AAVLP-OVA (100µL) + Mont (100µL)  (n=5) 
Table 2.1: Immunization scheme. 
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 Enzyme-linked immunosorbent assay 2.2.1.1
To evaluate specific IgG1 and IgE responses in different immunization groups, blood 
samples were drawn by tail bleeding after each immunization round and centrifuged 
following clotting for collecting the sera. Sera were analyzed individually by enzyme 
linked immunosorbent assay (ELISA). OVA (c=2µg/mL) or wtAAVLP (c=5.0E + 9 
capsids/well) were coated overnight at 4°C, 100µL/well. Wells were washed five times 
(200µL/well) with 0.05% Tween 20 in Tris buffered saline (TBST). After blocking with 
1% milk powder/TBST, mouse sera were diluted 1:10 for IgE and 1:100 for IgG1 in 
0.1% milk powder/TBST and incubated over night at 4°C. Standard IgG1 and 
standard IgE were solubilized in 0.1% milk powder/TBST and incubated with a 
starting concentration of 500ng/mL, in 1:2 serial dilutions. Wells were washed before 
the incubation with primary detection antibodies rat-anti-mouse IgG1 and rat-anti-
mouse IgE. After washing the secondary detection antibody, goat-anti-rat-IgG-HRP, 
each 100µL/well was incubated for one hour at room temperature and one hour at 
4°C. The reaction was developed with ABTS solution (citric acid buffer, 1mg/mL 
ABTS, 0.1% H2O2) and the color reaction evaluated at an optical density of 405nm – 
490nm with a microplate reader. 
 
 β-hexosaminidase-release assay 2.2.1.2
To evaluate the anaphylactogenic potential of the AAVLP vaccine, mouse sera were 
tested in a β-hexosaminidase-release assay. β-hexosaminidase is released during 
degranulation of mast cells. RBL-2H3 basophil cells were plated with a concentration 
of 4x104 in 100µL/well in a 96-well round bottom plate to adhere overnight at 37°C at 
5% CO2. Cells were passively sensitized with pooled mouse sera diluted 1:10 for two 
hours at 37°C at 5% CO2. Supernatants were then discarded and cells were washed 
twice with 0.1% BSA/Tyrode’s buffer (200μL).  
1L Tyrode’s buffer: 9.5g tyrode salts, 0.2g CaCl2, 0.2gKCl, 0.0469g MgCl2(anhyd.), 8g 
NaCl, 0.05g NaH2PO4.H2O, 1g D-Gucose, 2.38g 10mM HEPES, 1g NaHCO3, ad 1L 
H2O, pH=7.2 
For the stimulation ovalbumin, Phl p 5 as irrelevant allergen (0.1µg/mL, 0.5µg/mL, 
1.0µg/mL in 100µL/well) and ionomycin as positive control (0.4µg in 100µL/well) were 
diluted in Tyrode’s buffer without any allergen and 10% Triton X-100 were 
supplemented (10µL) for 10 minutes to achieve 100% β-hexosaminidase-release. 
50µL of supernatant were transferred to a flat bottom plate and incubated with 50μL 
of β-hexosaminidase assay solution [5mL citrate buffer (0.1M citric acid, pH=4.5), 
80µL 4-MUG] for one hour at 37°C. Reaction was stopped by adding 100µL glycine 
buffer (15g glycine, 11.7g NaCl, 1L H2O, pH=10.7) and fluorescence was measured 
 35 
at 360-465nm in a fluorometer (Cytofluor 2350, Millipore). Results were calculated as 
% of the total release. 
 
 Anaphylaxis experiment 2.2.2
To study safety aspects in vivo, allergy and anaphylaxis experiments were performed 
after the three immunizations. To induce anaphylactic reactions, mice were 
challenged intravenously with OVA (1mg/ml in 50µL 0.9% NaCl). Rectal temperature 
was measured before and 20 minutes after the challenge.  
 
 Type I skin test  2.2.2.1
For in vivo type I hypersensitivity skin testing, naïve and OVA sensitized mice (n=5 
per group) were used. OVA, in combination with aluminum hydroxide, a known TH2 
adjuvant, was vaccinated three times intraperitoneally to achieve hypersensitivity. 
100µL Evans blue (c = 5mg/mL) were injected into the tail vein of mice. Subsequently, 
30 µL of 48/80 histamine releasing substance (40µg/mL) as positive control, 30 µL of 
OVA (5µg/mL) and AAVLP-OVA particles (1.2E + 13 capsid/mL) were administered 
intradermally into the shaved abdominal skin. For negative control purposes 30 µL of 
irrelevant allergen Phl p 5 (5µg/mL), wtAAVLP (1.0E + 13 capsid/mL) and PBS were 
used. After 20 min mice were euthanized and type I responses evaluated. Upon 
specific mediator release the abdominal skin is colored blue due to vascular leakage.  
 
 Spleen cell preparation 2.2.2.2
Spleens of sacrificed mice were removed to isolate immune cells. Spleens were 
prepared in Petri dishes with RPMI 1640 media supplemented with 10% FCS, 2 mM 
L-glutamine, penicillin (100 U/mL), and streptomycin (100µg/mL). To receive a cell 
suspension, spleens were meshed and filtered through 70µm nylon sieve, which were 
layered over 5mL Lympholyte. Lymphocytes were extracted by density separation via 
centrifugation at 2240rpm for 20 minutes and washed three times with 10mL media by 
centrifugation at 1500rpm for 10 minutes. Cells were cultivated in a concentration of 
4x105/well in sterile 96-well round-bottom plates and stimulated with 20µg/mL OVA, 
20µg/mL Phl p 5, for positive control purposes with 5µg/mL Concavalin A and for 
negative control with media for 72h at 37°C. After incubation, plates were centrifuged 
5 minutes at 1500rpm. 170µL of the supernatant were removed and transferred into a 
12 well flat-bottom plate were it was stored at -20°C until further use for cytokine 
testing. 
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 IL-5 Cytokine ELISA 2.2.2.3
Supernatants of stimulated spleenocytes were analyzed for IL-5 production using the 
IL-5 ELISA-Kit from eBioscience according to the manufacturer’s instructions. 
 
2.3 Methods: AAV HER-2 mimotope experiment 
 Cell culture 2.3.1
Cells [D2F2-E2, D2F2, TAUF1.1, CT26, (m)BT474] were suspended in 10mL media 
and centrifuged at 1200rpm for three minutes. The pellet was resuspended in media 
(15mL) before cells were seeded in 75cm² cell culture flasks and incubated at 37°C in 
humidified atmosphere of 5% CO2. When reaching a confluence cells were split to 
maintain exponential growth. For this purpose cells were washed with 5mL PBS 
before being trypsinized with 0.05% trypsin – EDTA (1 – 2mL). The enzymatic 
reaction was stopped by adding an excess of fetal calf serum (FCS), a component of 
the media. Cell – trypsin – medium suspension was centrifuged at 1200rpm for four 
minutes, the pellet was resuspended and seeded again in a new flask for incubation 
at 37°C in a 5% CO2 atmosphere.  
 
 rHER-2 purification 2.3.2
Lec-HER-2 cells were cultivated in DMEM/F12 Media supplemented with FCS, L-
glutamine, penicillin, streptomycin and geneticin G418, as described above. Cells 
secrete recombinant HER-2 (rHER-2) into supernatant, which was collected and 
stored at -20°C until further purification. 
 
 rHER-2 purification with Ni-NTA mini columns 2.3.2.1
Lec-HER-2 supernatants were mixed with equilibration buffer (NPI-10* buffer, 
according to manufacturer’s instructions, Quiagen Kit) in an 1:5 equation. Ni-NTA mini 
columns were equilibrated with 600µL NPI-10* by a two minute centrifugation at 
2900rpm. Columns were then loaded twice with 600µL supernatant-buffer mixture 
which was centrifuged at 1600rpm for five minutes. Flow through was removed and 
columns were then washed twice with 600µL NPI-10* for two minutes at 2900rpm. To 
eluate the proteins, columns were loaded three times with 300µL NPI-250 and 
centrifuged at 2900rpm for two minutes.  
These eluates were concentrated by centrifugation (3500rpm, 5-8 minutes) with an 
Amicon ultra-15 centrifugal filter tube and dialyzed over night at 4°C against sterile 
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aqua double distilled or sterile PBS with a dialysis cassette 10.000 MWCO. Dialyzed 
rHER-2 was stored at -20°C until further detection. 
 
 rHER-2 purification with Ni-NTA agarose beads 2.3.2.2
To increase the protein amounts purified from Lec-HER-2 supernatants, we improved 
the method using Ni-NTA agarose beads instead of mini columns.  
NPI-10* buffer was mixed 1:10 with Lec-HER-2 supernatant before Ni-NTA agarose 
beads (1:100) were added and incubated overnight at 4°C under continuous agitation. 
The next day supernatant beads mixture was loaded onto a polyprep column which 
was washed with 15mL NPI-10* buffer. Eluation was done step by step with 100µL to 
150µL with NPI-250 buffer.  
Eluates were concentrated, dialyzed and stored as mentioned before. 
 
 SDS polyacrylamide gel electrophoresis 2.3.2.3
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE) is a method 
that separates a protein according to its mass. Electrophoretic mobility independent 
on molecular charges in the gel is guaranteed by charging the protein negatively with 
SDS (provided by Laemmli sample buffer). For HER-2 detection an 8% 
polyacrylamide gel was prepared: 
 
Separation  gel  Stacking  gel  
 Aqua dest. 4.76mL  Aqua dest. 2.4mL 
 Running buffer 2.5mL  Stacking buffer 1.25mL 
 10% SDS 100µL  10% SDS 50µL 
 30% Acrylamide 2.6mL  30% Acrylamid 1.3mL 
 10% APS 50µL  10% APS 25µL 
 TEMED 10µL  TEMED 10µL 
Table 2.2: 8% SDS PAGE. 
 
Purified proteins were mixed at equal parts with reducing loading buffer and were 
incubated for three minutes at 95°C. Prepared samples and the marker PageRulerTM 
Plus prestained protein ladder (Thermo Scientific) were loaded onto the PA Gel and 
run at 200V, 60mA in electrophoresis buffer for one hour. Afterwards the gel was 
rinsed in water before it was stained for two hours with Coomassie brilliant blue and 
destained over night with Coomassie destainer. 
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 Protein detection with Pierce BCA protein assay 2.3.2.4
For quantification of purified HER-2, Piece BCA protein assay kit was used as 
detection method according to the manufacturer’s instructions. A standard curve with 
different concentrations of BSA was plotted, setting up an appropriate equation for 
calculating the concentration of purified HER-2. 
 
 Flow cytometric analysis 2.3.3
For chosing a tumor cell line for the tumor transplantation experiment, flow cytometric 
analysis was performed to verify HER-2 surface expression. The HER-2 expressing 
D2F2-E2 and TAUF1.1 tumor cells were compared to the non-HER-2 expressing 
D2F2 and CT26 tumor cells. Therefore, cells were harvested, counted and portioned 
in a concentration of 2.5 x 105 cells in 1mL FACS buffer (PBS, 5% normal goat sera) 
per tube. Tastuzumab and controls were added into appropriate samples, mixed and 
incubated at 4°C for 30 minutes. Cells were washed with 2mL FACS buffer by 
centrifugation at 1200rpm for three minutes, before adding the secondary FITC 
labeled antibody to resuspended cells. After an incubation at 4°C for 30 minutes, cells 
were washed again with 2mL FACS buffer and afterwards solubilized in 500µL FACS 
FIX buffer (FACS buffer, 1% paraformaldehyd) for analysis using FACS Calibur. 
 
 Tumor titration experiments 2.3.4
For tumor transplantation, a defined tumor cell line had to be chosen, comparing 
D2F2-E2 and TAUF1.1 with the non-HER-2 expressing cell lines D2F2 with CT26, 
respectively. For this purpose, an in vivo titration experiment was performed using 
naïve female BALB/c mice. 
After reaching appropriate cell density, cells were resuspended in PBS and adjusted 
to cell numbers of 1x106 or 1x107 in 100µL solution, and injected subcutaneously into 
naïve BALB/c mice. D2F2-E2 cells were implanted on the right flank, D2F2 on the left 
side using the same cell number. In the other groups of mice, CT26 cells were 
implanted on the right flank and TAUF1.1 on the left side, again using the same cell 
number in each individual. 1x106 tumor cells were transplanted into two mice each 
and 1x107 into four mice. Tumor growth was monitored by palpation and caliper 
measurement every day. 
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 Specificity test of HER-2 mimotopes displayed by AAV particles 2.3.5
All AAV HER-2 mimotope clones and the carrier wtAAV were tested for specificity in 
ELISA. 100µL/well of 1µg/mL anti-HER-2 antibody trastuzumab (Herceptin®) and as 
isotype controls the anti-CD20 antibody rituximab, as well as the anti-EGFR antibody 
cetuximab were coated onto ELISA plates and incubated overnight at 4°C. After 
blocking with 1% BSA in PBST (0.05% Tween) for one hour at room temperature and 
one hour at 4°C, followed by washing with PBST, particles were diluted in 0.1% BSA / 
PBST in the following concentrations:  
DMD1, DMD2, wtAAV (negative control): 1µg/mL, 0.5µg/mL, and 0.1µg/mL, (here, 
clones DMD1 and DMD2 are exemplarily applied). 
The particles were incubated under soft agitation for 2 hours at room temperature 
before they were washed again. Anti-AAV antibody was diluted 1:20 in 0.1%BSA / 
PBST and incubated for one hour at 37°C. For detection streptavidin-HRP was diluted 
1:1000 in PBST and incubated for another hour at room temperature. The reaction 
was developed with ABTS substrate solution and the color reaction recorded at an 
optical density of 405nm – 490nm in a microplate reader. 
 
 Mouse immunization I. 2.3.6
AAV particles displaying different HER-2-mimotopes on their surface (table 2.3) were 
used for immunizations of eight weeks old female BALB/c mice (n=8). Vaccination 
was performed subcutaneously into the nuchal fold three times with intervals of two 
weeks (figure 2.3). In this first approach Montanide ISA 51 VG® was used as 
adjuvant. 
 
Table 2.3: Immunization groups of HER-2 experiment I. 
 
Groups/ Particles  Concentration Montanide® 
A/ DMD1 100µL 100µg/mL 100µL 
B/ DMD2 100µL 100µg/mL 100µL 
C/ DMD4 100µL 100µg/mL 100µL 
D/ DMD15 100µL 100µg/mL 100µL 
E/ DDD19 100µL 100µg/mL 100µL 
F/ VP3-TTSN(*) 100µL 100µg/mL 100µL 
G/ Naïve    
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To evaluate specific immune responses in different immunization groups, blood 
samples were drawn by tail vein bleeding after each vaccination round to gain mouse 
sera. 
 
Figure 2.3: AAV HER-2 mimotope immunization experiment I. 
 
 ELISA for testing immunogenicity against rHER-2 2.3.7
According to the protocoll described above in 2.3.1.1, pre-/ mouse immunsera were 
analyzed individually by ELISA for immunoglobulin reactivity against rHER-2 (coating 
1µg/mL). After blocking and washing, mouse sera were diluted 1:100 for total IgG. As 
positive control trastuzumab and as negative control rituximab were used. Wells were 
washed before incubation with detection antibody anti-mouse-IgG-HRP (for sera 
detection), or anti-human-IgG-HRP (for control detection), each 100µL/well, for one 
hour at room temperature and one hour at 4°C. The reaction was developed with 
ABTS solution and color reaction evaluated at an optical density of 405nm – 490nm. 
 
 Immunofluorescence 2.3.8
D2F2 and D2F2-E2 were seeded for a concentration of 2x105 cells in 400µL per well 
on four-well immunofluorescence chamber slides (Permanox®, Thermo Scientific). 
After 24 hours they were fixed with 4% paraformaldehyde for 8 minutes at room 
temperature before they were washed three times with cold PBS. For DAPI staining, 
cells were permeabilized 5 minutes with 0.5% TritonX-100 in PBS and washed again 
with cold PBS. Sera were diluted 1:20 in PBS/ 0.5% BSA with 200µL each well, 
whereas trastuzumab and rituximab were incubated with 1µg/mL each. After an 
incubation of one hour at room temperature, wells were washed four times with cold 
PBS, before the secondary antibody, diluted 1:200 in PBS/ 0.5% BSA was added in 
400µL per well. Incubation was performed by covering slides with aluminum foil for 45 
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minutes, and stopped by washing slides four times with cold PBS. DAPI diluted 
1:5000 was incubated for eight minutes at room temperature and then washed three 
times with cold PBS. 
Afterwards all slides were washed in distilled aqua before they were covered with 
mounting medium (FluoromountTM, Sigma) and stored at 4°C. 
  
 Tumor transplantation I. 2.3.9
After deciding on the tumor cell clone D2F2-E2 and D2F2 with cell numbers of 1x107 
per mouse, cells were cultured for the transplantation experiment. Cells were washed 
with PBS and trypsinized before they were counted and diluted in sterile PBS. D2F2 
cells were implanted on the left flank, D2F2-E2 on the right side using same cell 
numbers (1x107 in 100µL). Remnants were used for FACS analysis to verify correct 
HER-2 expression directly before grafting. Tumor growth was monitored by caliper 
measurement at a daily basis to plot a growth curve. 
 
 Mouse immunization II. 2.3.10
Medigene supported new HER-2 AAV mimotope clones, which were this time 
immunized (n=8 per mouse group) with aluminum hydroxide instead of Montanide 
ISA as an adjuvant (table 2.4). To achieve a better immune response, four 
immunizations were planned with intervals of ten days (figure 2.4). 
 
Table 2.4: Immunization groups of HER-2 experiment II. 
Groups/ Particles  Concentration Alum 
A/ DMD1 100µL 100µg/mL 100µL 
B/ DMD2 100µL 100µg/mL 100µL 
C/ DMD4 100µL 100µg/mL 100µL 
D/ DMD6 100µL 100µg/mL 100µL 
E/ DMD15 143µL 70µg/mL 100µL 
F/ DDD19 120µL 83µg/mL 100µL 
G/ DMM44 100µL 100µg/mL 100µL 
H/ wtAAV 143µL 70µg/mL 100µL 
J/ rHER-2 100µL 50µg/mouse 100µL 
K/ Naïve    
L/ 4D5 100µg/mouse 2.5mg/mL passive Imm. 
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Figure 2.4: AAV HER-2 mimotope immunization experiment II. 
 
 ELISA for testing immunogenicity against rHER-2 2.3.11
To test the immune response resulting from the second AAV HER-2 mimotope 
vaccination, ELISA was performed comparing the immunoglobulin reactivity against 
rHER-2 of pre immune sera and 1st to 4th mouse immune sera according to the 
protocol described above in 2.3.7, using the antibodies rat anti-mouse IgG1 and goat 
anti-rat IgG-HRP for detection. 
 
 Tumor transplantation II. 2.3.12
After complete immunization, a repetition of the in vivo tumor experiment was 
performed. This time, only the HER-2 expressing cell line D2F2-E2, with a cell 
number of 1x107 was chosen.  
As an additional control, 4D5 antibody, the murine precursor of the clinically used 
humanized anti-HER-2 antibody trastuzumab was passively applied (100µg/mouse) 
as positive control by passive immunization. Also rHER-2 was used as a control 
immunogen solubilized in sterile PBS (50µg/mouse). 
Because of the invasive and aggressive tumor growth of D2F2 cells, only the HER-2 
expressing cell line, D2F2-E2 was used for further tumor transplantation, but cell 
numbers 1x107 remained unchanged due to most homogeneous growth behavior. 
 
 Histology 2.3.13
Tumors of sacrificed mice were collected, washed with PBS and chemically fixed in 
4% paraformaldehyde to avoid autolysis, decay and decomposition. Paraffin is 
insoluble in water and in alcohol, so four steps were necessary for embedding: 
dehydration, intermediate, saturation in paraffin and solidification. In the last step 
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tumors were formed into blocks by paraffin effusion and by cooling them down 
quickly. Afterwards paraffinated tumor blocks of naive, rHER-2 and 4D5 group were 
cut into 4µm sections and histologically stained with hematoxilin – eosin, which colors 
nuclei blue and eosinophilic structures in different red colors. For testing HER-2 
expression directly on tissue, sections were immunohistochemically stained with 
HerceptTest®, where membrane bound HER-2 is colored brown and the rest is 
stained blue (kind support by Prof. R. Horvath, Clinical Institute of Pathology, Medical 
University of Vienna). 
 
 Proliferation assay 2.3.14
D2F2-E2, D2F2, TAUF1.1, CT26, BT474 or mBT474 cells were seeded in 96-well 
round-bottom plates with a concentration of 2x104 cells in 100µL media and incubated 
over night at 37°C in a humidified atmosphere of 5% CO2.  
After 24 hours, cells were stimulated with 1µg/well trastuzumab, rituximab or 
cetuximab solubilized in sterile PBS. Alternatively, purified mouse IgGs from AAV-
mimotope immunized mice (5µg/well) was applied (protocol for antibody purification 
listed below). For control purposes 1µg/well of 4D5 was used. For further control 
purposes cells alone and media alone were also used. After 24, 48, 72 hours 
10µl/well EZ4U® assay substrate (tetrazolium-based) was added and incubated for 
three hours at 37°C. Supernatants were transferred into 96-well flat-bottom plates and 
the signal determined at optical density of 450nm – 620nm using a microplate reader. 
 
 Antibody purification 2.3.15
For proliferation assays, HER-2 specific antibodies were purified from preimmune 
sera and fourth immune sera with protein G sepharose beads. Single sera of groups 
were pooled at equal parts. 150µL or 250µL protein G sepharose beads with a 
binding capacity of around 20mg/mL were added into each pool of PIS and 4th MIS. 
The sera/beads mixture was incubated overnight at 4°C under constant agitation. On 
the next day, the mixture was spun down and Ni-NTA columns were equilibrated with 
1mL 10mM Tris/HCl. Afterwards sera/beads mixtures were loaded and the flow 
through collected. Columns were washed with 2mL 100mM Tris/HCl and then with 
2mL 10mM Tris/HCl buffer before they were eluted twice with 1mL 0.1M glycine at pH 
2.5 and neutralized with 1/10 1M Tris/HCl. 
Eluates were afterwards loaded onto MicroSpin™ columns to make a buffer 
exchange from a glycine Tris/HCl buffer to aqua double distilled. 
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Consequently, quality of purified IgG antibodies was tested by SDS PAGE and 
specificity by ELISA, coating 1µg/mL rHER-2 and using 1µg/mL 4D5 antibody for 
control purposes (according to the protocol described in 2.3.7). Purified antibodies 
were adjusted to 3µg/mL for incubation and tested for the presence of IgG1, IgG2a or 
IgG2b antibodies. Rat anti-mouse IgG1, IgG2a or IgG2b were used as primary 
antibodies and goat anti-rat IgG-HRP for detection using TMB substrate for 
development. Substrate A and B were mixed at equal parts pipetting 100µL into each 
well. The reaction was stopped with 100µL/well 1.8M H2SO4 and detected at an 
optical density of 450nm – 630nm in a microplate reader. 
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3 Results 
3.1 AAVLP OVA experiment  
 Immunogenicity of AAVLPs 3.1.1
In the first part of this thesis project AAVLPs were examined for immunogenicity and 
safety using an 18 amino acid OVA B-cell epitope displayed by AAVLPs as a model 
system. Mice were immunized three times in bi-weekly intervals and the induced IgG1 
and IgG2b antibodies were monitored by ELISA, comparing the preimmune antibody 
titers (PIS) with those induced by 1st – 3rd MIS. The allergen OVA was coated for 
determining the antigen specific response, wtAAVLP particles were coated for 
evaluating the anti-carrier response. The columns in figure 3.1 A – D indicate mean 
values plus/minus standard deviation of all determined single values. As expected, all 
mice immunized with AAVLP presented comparable anti-carrier responses (figure 3.1 
B.). In contrast, only groups immunized with the OVA peptide displayed by AAVLPs 
developed an OVA-specific IgG1 response (figure 3.1 A.). The induced IgG was 
dominated by IgG1, whereas antibody class IgG2b was only detectable at 
background levels (C. and D.). Groups immunized with Alum as adjuvant showed 
higher specific IgG1 antibody titers, than groups vaccinated with Montanide. 
Moreover, antibody titers were not only higher, but also more homogeneous in sera 
vaccinated with aluminum hydroxide than with Montanide. This is illustrated in E. and 
F., where results of single sera are shown individually. 
 
A       B 
 
 
 
 
 
OVA-specific IgG1 wtAAVLP-specific IgG1 
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C       D 
 
 
 
E       F 
 
 
Figure 3.1: Specific antibody detection by ELISA. A.: OVA-specific IgG1. B.: wtAAVLP-specific 
IgG1. C.: OVA-specific IgG2b. D.: wtAAVLP-specific IgG2b. E.: OVA-specific IgG1 of 3
rd
 MIS 
AAVLP/Alum. F.: OVA-specific IgG1 of 3
rd
 MIS AAVLP/Mont. 
 
 In vitro safety aspects of AAVLPs 3.1.2
The question whether AAVLP displayed mimotopes would induce hypersensitivity 
was addressed by in vitro experiments. First, it was tested whether IgE, the 
anaphylactogenic class of immunoglobulins, was induced by any of the treatments or 
vehicles. Figure 3.2 A. shows that there was no IgE in any of the AAVLP-immunized 
groups. To evaluate the functional anaphylactogenic potency of the AAVLP vaccine, 
mouse sera were pooled of each group and analyzed using a β-hexosaminidase-
release assay. RBL (rat basophile leukemia) cells harbor the high affinity IgE receptor 
and may be sensitized with IgE by serum incubation, in case IgE is contained. Upon 
allergen challenge, RBL release from their granula β-hexosaminidase. Because of the 
fact, that no IgE was present in AAVLP immunized groups, RBL cells were not able to 
degranulate and release β-hexosaminidase. Thereby the safety of the vaccine could 
OVA-specific IgG2b wtAAVLP-specific IgG2b 
OVA-specific IgG1 (AAVLP/Alum) OVA-specific IgG1 (AAVLP/Mont) 
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be affirmed in vitro (figure 3.2 B.). As expected, the reference group “OVA-immunized 
mice” contained IgE in their sera which was functional in the RBL assay and led to 
mediator release. 
 
A       B 
 
 
 
Interleukin 5 (IL-5) is a cytokine responsible for eosinophilic granulocyte 
differentiation. It is secreted by TH2 helper cells and elevated IL-5 level indicate a TH2-
shift of the immune response. The above observed IgG1 antibodies were suggestive 
for a TH2 immunomodulatory property of the AAVLP-OVA vaccine at least in context 
of the selected adjuvant Alum or Montanide. To further investigate this, spleenocytes 
were isolated and cultured from the mice of each group, stimulated with OVA and 
supernatants collected and subjected to cytokine ELISA. Figure 3.3 illustrates AAVLP 
immunized groups secreting IL-5 only at background levels, whereas higher levels of 
IL-5, although not significantly, were determined in OVA-immunized group.  
 
 
Figure 3.3: Detection of IL-5 cytokine from spleenocytes ELISA. No significance: ns p>0.05. 
Figure 3.2: A.: IgE (3
rd
 MIS) on OVA in ELISA. B.: β-hexosaminidase-release assay. 
p=1.40 
p=1.36 
OVA specific IgE (3
rd
 MIS) β-hexosaminidase-release 
IL-5 
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 In vivo safety aspects of AAVLPs 3.1.3
 Anaphylaxis experiments 3.1.3.1
A drop of body temperature is a typical symptom of anaphylaxis and can be easily 
evaluated. All mice of each group were challenged intravenously with OVA and rectal 
temperature measured before and 20 minutes after the challenge (figure 3.4). 
Whereas the OVA-immunized positive control group displayed a significant 
temperature difference (36.5° - 30.5°C), the AAVLP-OVA immunized groups 
remained stable, indicating no anaphylactic reaction in any of the AAVLP immunized 
mice.  
 
 
Figure 3.4: Rectal temperature. Significance: *** p<0,001 
 
Physical activity is also reduced during anaphylaxis. Also this typical symptom was 
exclusively observed in the OVA challenge in OVA-immunized group and mirrored the 
results of the body temperatures (not shown). 
 
  Type I hypersensitivity skin testing 3.1.3.2
From the above experiments with the AAVLP-displayed OVA epitope we learned that 
most likely, the vaccine does not induce allergy, but rather immunity. However, how 
safe would the vaccine be in an already sensitized organism? This aspect would be 
relevant for the application of AAVLPs for a possible later development of a vaccine 
for allergics. Therefore, we additionally tested safety aspects in specifically sensitized 
mice. Naïve and OVA i.p. sensitized mice were challenged intradermally with 
substances indicated in figure 3.5. In case an allergen specifically binds to cell-fixed 
IgE, productive cross-linking and mediator release is achieved, rendering, vascular 
leakage occurs, visible as blue color exsudating into the skin. In the naïve group only 
Rectal temperature 
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positive control histamine-releasing substance 48/80 induced a histamine release 
resulting in blue coloring of the skin. OVA-sensitized mice showed positive reactivity 
to 48/80 and, as expected, to challenges with OVA. AAVLP-OVA produced negligible 
coloring. No systemic reactions were observed in any of the challenged mice. This 
result indicates that in allergic patients, only immediate local side effects may be 
expected with an AAVLP-vaccine displaying an allergen or allergen subunit. On the 
other hand no type I skin reactivity was observed from challenges with the carrier 
AAVLP clones confirming tolerability of the vaccine. 
 
 
Figure 3.5: Type I skin test of naïve and OVA i.p. sensitized mice. Panels bottom, left; mouse 
1: note exsudation of OVA reaction into field.  
 
3.2 AAV HER-2 mimotope experiment 
 rHER-2 specificity 3.2.1
For testing antibody specificity, rHER-2 was produced and quality was proved by a 
Coomassie blue stained SDS polyacrylamide gel. Figure 3.6 illustrates several protein 
fragments, due to destruction of hydrogen bonds within the protein induced by β-
mercaptoethanol, a component of the sample buffer. 
 
 
   
 
 
 
 
 
 
Specificity of purified rHER-2 was affirmed by the anti-HER-2 antibody trastuzumab in 
ELISA. Negative controls anti-CD20 antibody rituximab and anti-EGRF antibody 
cetuximab did not bind to rHER-2 and attested therefore specificity of the purified 
antigen (data not shown).  
Figure 3.6: Purified recombinant HER-2 analyzed by Coomassie blue stained SDS 
polyacrylamid gel electrophoresis. 
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 Tumor titration experiments 3.2.2
Before tumor transplantation, flow cytometric analysis was performed to verify HER-2 
surface expression of the tumor cells D2F2-E2 and TAUF1.1 compared to non-
expressing D2F2 and CT26 tumor cells (figure 3.7). The typical red shift demonstrates 
HER-2 expression recognized by the monoclonal antibody trastuzumab. Blue 
indicates isotype control. 
 
 
 
 
 
 
Figure 3.7: HER-2 expression status of D2F2-E2, D2F2, TAUF1.1 and CT26 cells. The 
characteristic red shift determines HER-2 expression. Blue shows isotype control. 
 
The HER-2 expressing cell lines D2F2-E2 and TAUF1.1 versus the non-expressing 
D2F2 and CT26 were cultivated and transplanted into naïve BALB/c mice at different 
cell numbers (1x106 and 1x107). The growth of HER-2 expressing and non-expressing 
cells within the same individual was compared injecting each cell type into left or right 
flank. D2F2 and D2F2-E2 showed a more homogeneous tumor growth than CT26 
and TAUF1.1 (figure 3.8). Apparently D2F2 were the most succesfully and 
homogenously growing transplanted cells of all. With respect to the HER-2 expressing 
cells D2F2-E2 tumors occurred earlier, abaut day 4, than TAUF1.1, which started 
growing at day 9. Based on these preexperiments D2F2-E2 and its parental cell line 
D2F2 were chosen for the following tumor transplant experiments in HER-2 mimotope 
immunized mice. 
 
A      B 
D2F2-E2 D2F2 
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C      D 
 
Figure 3.8: Tumor growth cuves of A. D2F2-E2, B. D2F2, C. TAUF1.1 and D. CT26 cells. 
 
 HER-2 immunization experiment I 3.2.3
 Specificity test of HER-2 mimotopes 3.2.3.1
HER-2 mimotopes were selected by Medigene from an AAV display library by the 
anti-HER-2 antibody trastuzumab. Figure 3.9 illustrates that clones specifically bound 
to trastuzumab, taking DMD1 and DMD2 as examples (A), whereas the signal against 
rituximab (B) and cetuximab (C) as negative controls remained negative. Further, 
empty wtAAV did not give any signal indicating the antigen specificity of the assay. 
Based on these results the HER-2 mimotope displaying AAV particles were ready for 
immunization experiments.  
 
 
A      B      C 
 
 
 
 
 
 
 
 
 
Figure 3.9: The HER-2 mimotope displaying DMD1 and DMD2 particles showed specific 
binding to the anti-HER-2 antibody trastuzumab in ELISA.  
 
Rituximab Trastuzumab Cetuximab 
TAUF1.1 CT26 
 52 
 AAV mimotope immunizations prime specific anti-HER-2 IgG 3.2.3.2
During the cause of immunization with HER-2 mimotopes, immune sera were 
collected and tested for the presence of HER-2 specific immunoglobulins in ELISA. 
Figure 3.10 shows that the IgG response increased during vaccination, also to a 
certain degree in mice immunized with particles presenting an unspecific peptide 
TTSN. However, when consecutively all mice were challenged with HER-2 
overexpressing D2F2-E2 cells only HER-2 mimotope immunized mice responded with 
high levels of HER-2 specific total IgG. This result indicates that the AAV mimotope 
immunizations primed a HER-2 specific immune response against the cellularly 
expressed antigen. Clone DMD1, DMD2 or DMD15 achieved higher titers against 
rHER-2 compared to other groups. Homogeneity of the immune response within in 
one group can be seen in figure 3.11, where individual sera are shown. 
 
 
 
Figure 3.10: Immune response, total IgG of pooled sera on rHER-2. 
 
 
 
 
 
 
 
 
 
 
In this immunization experiment Montanide was used as adjuvant, which turned out to 
be complexe to handle and causing massive granuloma formation.  
Figure 3.11: The homogeneity of immune response, in mouse groups is demonstrated 
exemplarily in the group B immunized with clone DMD2. B1-B8 indicate individual mice. 
HER-2 specific total IgG 
HER-2 specific total IgG (DMD2 immunized mice) 
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 Immunofluorescence 3.2.3.3
To further demonstrate the specificity of the above described immune response, 
immunofluorescence was performed with the HER-2 overexpressing cell line D2F2-
E2 and also for control purposes with the parental cell line D2F2. Exemplarily for all 
results, immunofluorescence with sera of mice immunized with clone DMD15 is 
shown in figure 3.12.  
DAPI staining of nuclei is visible in blue. HER-2 specific signals are stained by green 
fluorescence (FITC), the positive control Herceptin demonstrates HER-2 receptor 
distribution along the membrane. No reaction could be detected in D2F2 cells or in 
any pre-immune sera. In accordance with ELISA results, a specific signal could only 
be detected after priming with the natural antigen. 
 
A   B   C   D 
 
 
 
 Transplantation experiment in HER-2 mimotope immunized mice 3.2.3.4
D2F2 cells were implanted on the left flank, D2F2-E2 on the right side of each mouse, 
using 1x107 cells. Tumors were monitored daily by palpation and caliper 
measurement (figure 3.13). Albeit the high and specific IgG titers no difference in 
tumor growth of HER-2 expressing and non-expressing cells could be observed.  
Figure 3.12: Immunofluorescence performed with D2F2 cells and D2F2-E2 cells incubating 
them with trastuzumab, DMD15 PIS, 2
nd
 MIS and 3
rd
 MIS (from A to D) 
 
Trastuzumab DMD15 PIS DMD15 2
nd
 MIS DMD15 3
rd
 MIS 
D2F2 
D2F2-E2 
D2F2 D2F2 D2F2 
D2F2-E2 D2F2-E2 D2F2-E2 
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A         B 
 
 
 
 
 
 
 
 
 
Figure 3.13: D2F2-E2 and D2F2 tumor growth. 
 
Notably, a previously performed tumor transplant experiment in mice immunized with 
a nonrelated mimotope had shown an effect on tumor growth after 12 days only 
(Weichselbaumer M. et al. is in progress). The aggressive growth of D2F2 cells in the 
present experiment did, however not allow maintaining mice alive longer than 12 
days. Therefore, an improved experimental design had to be developed for the proof 
of concept studies, termed HER-2 immunization experiment II, see below. 
 
 HER-2 immunization experiment II 3.2.4
 AAV mimotope immunizations prime specific anti-HER-2 IgG 3.2.4.1
For the repetition and improvement of the mimotope immunization study, clones 
DMD1, DMD2, DMD4, DMD15, DDD19 were selected again, and DMD6 and DMM44 
newly added. For comparison, purified rHER-2 and empty particles were vaccinated 
in control groups. Further, Alum was used as the adjuvant due to several 
disadvantages of Montanide (handling, granuloma formation) and the very positive 
results of the OVA study with Alum. Furthermore, four instead of three immunizations 
were performed. Again, blood samples of immunized mice were taken and ELISA was 
performed to evaluate the immune response against HER-2. Figure 3.14 (A.), 
illustrates that the HER-2 specific IgG1 immune response continually increased 
during vaccinations in all immune sera. Some AAV mimotopes provoked stronger 
IgG1 responses than others, whereas homogeneity inside the groups remained 
stable. Needless to say that the highest IgG1 titers were achieved with purified 
rHER-2.  
 
 
D2F2-E2 10^7 D2F2 10^7 
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A 
 
B 
 4
th
 MIS vs  Naïve significance 
DMD1   0.009 ** 
DMD2    0.000 *** 
DMD4   0.000 *** 
DMD6   0.000 *** 
DMD15   0.002 ** 
DDD19   0.000 *** 
DMM44   0.000 *** 
rHER-2   0.000 *** 
 
C 
 4
th
 MIS vs  wtAAV significance 
DMD1   0.878 ns 
DMD2    0.008 ** 
DMD4   0.000 *** 
DMD6   0.000 *** 
DMD15   0.674 ns 
DDD19   0.001 ** 
DMM44   0.036 * 
rHER-2   0.000 *** 
 
D 
PIS vs  4
th
 MIS significance 
DMD1   0,005 ** 
DMD2    0.000 *** 
DMD4   0.000 *** 
DMD6   0.000 *** 
DMD15   0.002 ** 
DDD19   0.000 *** 
DMM44   0.000 *** 
HER-2 specific IgG1 
HER-2 specific IgG1 
HER-2 specific IgG1 
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wtAAV   0.003 ** 
rHER-2   0.000 *** 
Naïve   0.023 * 
 
Figure 3.14: A. Means and standard deviation of IgG1 values determined in single 
immune sera tested on rHER-2 in ELISA. 
Significances comparing B. sera of 4th MIS versus naïve sera, C. 4th MIS versus the 
group immunized with the carrier particles alone, and D. pre-immune sera versus 
fourth immune sera. 
ns p>0.05; * p<0.05; ** p<0.01; *** p<0.001 
 
 Results of transplantation experiment in HER-2 mimotope immunized 3.2.4.2
mice 
A second tumor transplantation experiment was performed after completing four 
immunizations. This time using only the HER-2 expressing cells D2F2-E2 (1x107) 
which had been controlled for stable HER-2 expression by flow cytometric analysis 
(not shown). Additionally to the mimotope and HER-2 immunizations one group was 
treated passively with 4D5 antibody (100µg/mouse). Again, tumors were monitored 
daily by palpation and caliper measurement during a period of 17 days. However, 
similar to the first tumor experiment no significances were achieved comparing the 
single growth curves of differently immunized mice as compared to naïve or wtAAV 
groups (figure 3.15). The slowest growth curves, however, was achieved by 4D5 
antibody. The experiment was interrupted when tumors reached a size of 600mm3.  
 
 
Figure 3.15: Tumor growth curve of D2F2-E2 cells. 
D2F2-E2 10^7 
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 Histology 3.2.4.3
In order to find a possible explanation for the failure of the mimotope vaccine 
experiment grafted tumors were examined histologically for HER-2 expression. Figure 
3.16 illustrates a typical appearance of a grafted D2F2-E2 tumor at the inner face of 
the abdominal skin. Tumors of euthanized naïve (figure 3.17), rHER-2 (figure 3.18) 
and 4D5 (3.19) mouse groups were removed, paraffinated, cut and histologically 
stained with Hematoxylin Eosin and with the HercepTest®. Figures 3.18 to 3.20 show 
typical histochemical results. Each one example representative of the groups of 
naïve, rHER-2 and 4D5 treated mice is shown. Inside each tumor sections four zones 
are highlighted: picture A demonstrates marginal area of the skin with sebum glands 
and hair follicles, were infiltrating lymphocytes were found. Necrosis and ulceration is 
seen in areas highly stained with eosin, containing blood and damaged tissue (B,C). 
Picture D contains a high density of tumor cells with prominent nuclei, being colored 
strongly with hematoxilyn. 
Taken together, comparing the HER-2 staining in the different groups did not reveal 
any difference of expression levels. Thus, failure of target expression did not explain 
failure of the mimotope vaccination or 4D5 treatment. 
 
 
 
Figure 3.16: Tumor in vivo. 
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Figure 3.17: Tumor of one representative mouse from naïve group. 
A 
A 
B 
B 
C 
C 
D 
D 
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Figure 3.18: Tumor of one representative mouse from with rHER-2 immunized group. 
C 
A 
B D 
B 
D 
C 
A 
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Figure 3.19: Tumor of one representative mouse from group immunized passively with 4D5. 
A 
A 
B 
B 
D 
C 
D 
C 
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 Proliferation inhibition assay 3.2.5
From the above it was clear that although the AAV-mimotopes had induced 
considerable levels of anti-HER-2 antibodies, no biological anti-tumor effect was 
achieved using HER-2 high expressing cell line D2F2-E2 in the tumor transplant 
experiment. We therefore considered that D2F2-E2 could be driven by a strong HER-
2 independent autonomous oncogenic signal. To verify this, proliferation inhibition 
experiments were performed using trastuzumab as positive control and for isotype 
control purposes rituximab and cetuximab. Indeed, neither D2F2-E2 (Fig.3.20 A) nor 
TAUF1.1 (C) cells, both expressing the HER-2 transgene product on their surface, 
responded to trastuzumab stimulation. However, when we repeated the experiments 
with the human natural HER-2 overexpressing cell lines BT474 (E) and mBT474 (F), 
a significant growth inhibition upon trastuzumab stimulation could be observed after 
24h. 
 
A           B 
          D2F2-E2           D2F2 
 
 
C           D 
          TAUF1.1            CT26 
 
 
 62 
E      F 
   BT474       mBT474 
 
 
 
 
 
 
 
 
 
Figure 3.20: Results of proliferation assay of A. D2F2-E2, B. D2F2, C. TAUF1.1, D. CT26, E. 
BT474 and F. mBT474 cells. BT474 and mBT474 demonstrate a significant proliferation 
inhibition even after 24h incubation. 
 
 Antibody purification 3.2.6
The tumor transplant experiment had thus failed due to a non-responsiveness of 
D2F2-E2 cells to trastuzumab stimulation.  
As we considered that the well-responding cells BT474 and mBT474 could not be 
used for mouse grafting due to their human origin, we decided to prove the 
functionality of AAV-mimotope induced antibodies by in vitro assays. Therefore, we 
first had to purify IgG from the immune sera showing the highest titers. 
Antibodies from pooled preimmune sera and of sera after the forth immunization were 
purified with protein G sepharose beads; quantified by Pierce BCA protein assay and 
qualitatively analyzed in non-reducing SDS polyacrylamide gel electrophoresis (data 
not shown).  
 
Consequently, the specificity of the isolated mouse IgG was controlled by ELISA 
coated with purified rHER-2 and compared to 4D5 antibody (1µg/ml). Based on the 
calculated protein amounts in purified IgG fractions, samples were adjusted to 3µg/ml 
by dilution before incubation. Further, figure 3.21 illustrates that especially the isolated 
IgG from groups DMD1, DMD2, DMD4 and DMD6 contained IgG1 against HER-2 
antigen and were thus suitable for further in vitro analyses. Besides IgG1, IgG2a and 
IgG2b were tested showing only background levels (not shown). 
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Figure 3.21: IgG1 immune response of purified antibodies 3µg/mL compared to 1µg/mL 4D5 
(ELISA). X-axis indicates the mouse groups immunized with different AAV particles, from 
which IgG was purified. Y-axis shows OD values measured. 
 
Consequently, purified IgG1 from mouse groups immunized with AAV-mimotopes 
DMD1, DMD2, DMD4, DMD6 were applied in in vitro proliferation inhibition assay 
using BT474 and mBT474 cells. Figure 3.22 illustrates that after 24h incubation 
antibodies isolated from sera of DMD1 immunized mice induced highly significant 
growth inhibition in mBT474 and BT474 cells. The effect remained sustained up the 
72h in mBT474 cells, but rebound in BT474 cells. In contrast, antibodies from groups 
DMD4 and DMD6 showed a delayed effect in BT474 cells, but none in mBT474. 
In the moment we have no explanation for the different susceptibility of BT474 before 
and after passaging in SCID mice. 
 
 
A      B 
        BT474              mBT474 
 
 
 
 
 
 
 
 
 
Figure 3.22: Results of proliferations inhibition induced by purified antibodies in A. BT474 and 
B. mBT474 cells. 
 
 
HER-2 specific IgG1 
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Taken together, the AAV-displayed mimotopes were able to induce highly specific 
anti-HER-2 IgG1 response. The in vivo proof of concept failed due to selection of a 
non-responsive cell line for grafting. However, purified anti-HER-2 mimotope 
antibodies induced significant growth inhibition in an in vitro assay using BT474 and 
mBT474 cells as responsive tumor targets.  
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4 Conclusion 
Mammary carcinoma is one of the most malignant and common forms of female 
cancer. In about 25 – 30% of invasive breast cancers and in 70% of ductal carcinoma 
in situ, the human epidermal growth factor receptor HER-2 is overexpressed. This is 
associated with a worse prognosis, a decreased survival rate and disadvantages in 
responses to chemotherapeutic and hormonal anti-cancer agents [3,21].  
The advantage, however, in HER-2 overexpressing breast cancer is that targeting of 
this specific tumor antigen by passive immunotherapy with the humanized monoclonal 
antibody Herceptin® (trastuzmab) is possible. Trastuzumab binds the extracellular 
part of HER-2 and thus interferes with the HER-2 activated growth stimulatory 
signaling pathways. Yet passively applied IgG antibodies are of limited half-life and 
also their distribution in tissue differs enormously. To circumvent these problems we 
intended to design an active immunotherapy with memory effects against the HER-2 
tumor antigen. Cancer vaccines could be especially attractive for providing protection 
against recurrence during minimal residual disease. Further, we considered it 
important that an active immunotherapy should be able to induce antibodies of similar 
beneficial effects as the original trastuzumab antibody. This aim was pursued by the 
mimotope concept [22]. 
 
Mimotopes are small peptides with similar physical and biochemical properties as the 
antibody epitope on the original antigen. Tumor mimotopes, including HER-2 
mimotopes could already be generated repeatedly by our group utilizing phage-
display technology. Because of their low immunogenic activity, they were coupled to 
carrier molecules like KLH (keyhole limpet hemocyanin) or synthetically produced as 
octameric MAM (multiple antigenic mimotope). However, both strategies showed 
some draw backs, such as changes of antigenicity during chemical coupling. Our 
intention thus here was to optimize mimotopes by using a fusion molecule approach 
allowing assembling of AAVs and the production of AAVLPs, respectively [35,36].  
 
AAV are replication defective ssDNA viruses, non-pathogenic to humans and 
consisting of 60 capsomers, which makes them an attractive tool for vaccine 
technology. For specific surface display VP3 capsid proteins can be assembled to 
AAVLP with a B-cell epitope of interest. We used a B-cell epitope of ovalbumin as 
model epitope and compared it to a non-OVA related peptide (TP18) in the first part of 
the study [40-42].  
BALB/c mice were immunized subcutaneously with ovalbumin as positive and AAVLP 
as negative control groups, further with AAVLP displaying the OVA-B-cell epitope or 
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AAVLP-TP18 (negative control), and we used either aluminum hydroxide or 
Montanide ISA 51 as adjuvants. 
 
Our data show that AAVLPs as antigen carriers harbor good immunogenicity, as an 
anti-carrier response was noticed in AAVLP immunized groups. However, an OVA-
specific IgG1 immune response was achieved in AAVLP-OVA immunized groups 
only. Antibody class IgG2b was only detectable at background levels. This indicated 
specificity and immunogenicity of the AAVLP OVA model-vaccine. 
 
Next this AAVLP vaccine was tested for safety in respect to IgE induction and 
triggering of allergy. No IgE towards OVA was induced in AAVLP-OVA immunized 
group, compared to the positive control (OVA immunized mice). To verify this in vitro 
result a β-hexosaminidase release assay was performed. Thereby, in the presence of 
IgE RBL cells degranulate upon allergen trigger and release β-hexosaminidase, 
which can be measured by ELISA. Incubating RBL cells with sera from AAVLP 
immunized groups, no degranulation was obtained, confirming that no IgE was 
induced by the AAVLP-OVA vaccine or any of the AAVLP vaccines. 
 
Consequently an in vivo anaphylaxis experiment was performed by challenging all 
mice of each group intravenously with OVA. Rectal temperature typically drops during 
anaphylaxis and was therefore measured before and after the challenge. A 
temperature drop was only observed in the OVA-immunized positive control group, 
whereas all AAVLP immunized mice had a constant body temperature curve during 
monitoring. 
 
To complete all possible effects of allergy safety, i.e. vaccination safety in an already 
allergic subject, mice were sensitized i.p. with ovalbumin before they were vaccinated 
intradermally with different substances. OVA, but also AAVLP-OVA, though less 
intensely, showed type I skin reaction in the Evan’s blue test, while AAVLP alone did 
not induce Type I skin reactivity. These results indicated that AAVLPs used as 
carriers for B-cell epitopes have no de novo sensitization capacity. Further, in allergic 
patients with an allergen-AAVLP vaccine local minor, but no systemic side effects 
may occur. 
 
The overall aim of this master thesis, however, was to generate a HER-2 specific 
AAVLP mimotope vaccine. For these proof of concept studies instead of AAVLPs we 
were forced to used AAVs as display system as many clones had to be screened and 
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this of course caused manufacturing limitations. First off all immunogenicity and 
specificity of HER-2 AAV vaccines were evaluated in BALB/c mice. Low but 
increasing titers of total IgG antibodies against purified rHER-2 were indeed observed 
in the sera from mice immunized with several of the mimotope clones specific for 
trastuzumab. When subsequently D2F2-E2 cells were transplanted into them a boost 
of HER-2 specific IgG due to natural tumor antigen exposure was observed in ELISA 
as well as in immunofluorescence. This indicated that the HER-2 mimotopes, 
although of low immunogenicity were able to prime a highly specific IgG anti-HER-2 
response. 
 
HER-2 expression of cells had been verified before in flow cytometric analysis and the 
optimal number of cells to be transplanted by in vivo graft titration experiment. D2F2-
E2 (a HER-2 expressing murine breast cancer cell line) and D2F2 (its parental form) 
were subcutaneously transplanted, but D2F2 cells grew aggressively and also started 
to ulcerate from day 10, which forced us to terminate the experiment.  
 
Therefore, a second immunogenicity and specificity study was planned thoroughly, 
adding new and possibly better HER-2 mimotope clones, using this time four instead 
of three immunization rounds and Alum as an alternative adjuvant. ELISA results 
demonstrated a significant increase in IgG1 antibodies against rHER-2 compared to 
wtAAV or naïve groups.  
 
Consequently, the tumor transplant experiment was repeated, using only D2F2-E2 for 
transplantation without the heavily growing parental cell line D2F2. Although the 
experimental procedure had been improved, again no significances between tumor 
growth of different groups, could be achieved. Our immunohistological analysis using 
HercepTest® of tumors indicated that the treatment failure could not be explained by 
HER-2 down regulation during the experiment. It seemed thus probable that D2F2-E2 
cells, expressing HER-2 as a transgene product were not responding to HER-2 
targeting. To check that, murine HER-2 expressing D2F2-E2 and TAUF1.1 cells, in 
comparison to naturally overexpressing tumor cells BT474 and mBT474 were in vitro 
stimulated with trastuzumab and proliferation reacted as compared to isotype 
controls. Indeed, only human cancer cells showed significant and sustained 
proliferation inhibition.  
 
Hence, HER-2 was neither expressed functionally on D2F2-E2 nor on TAUF1.1 cells, 
providing an explanation for the failure of the in vivo experiment. This result suggests 
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that our HER-2 mimotope vaccine might be effective in the right model. Therefore, 
BT474 and mBT474 cell lines (the later being once transferred through a SCID 
mouse) were used for a proliferation inhibition assay using this time IgG antibodies 
purified from mimotope-immunized mice. Purified antibodies of clone DMD1 resulted 
in mBT474 tumor growth inhibition, equivalent to effects achieved with trastuzumab. 
Further, on BT474 cells the purified IgG induced by immunizing with AAV mimotope 
clones DMD4 and DMD6 showed anti-proliferative effects. These results thus 
evidenced in vitro tumor inhibitory effects of the AAV HER-2 mimotope vaccines when 
using responsive cell lines. As we considered that human BT474 cells cannot be 
transplanted into mice, an appropriate in vivo proof of concept is to this date still 
missing. 
 
Taken all data together, HER-2 mimotope AAVs are, in concert with the right 
adjuvant, highly immunogenic and able to actively induce immune responses to the 
specific antigenic epitope. AAV-display further does not prompt de novo sensitization. 
This master thesis thus presents a novel and safe approach using AAV-displayed 
HER-2 mimotope for channeling the immune system towards a specific and strong 
response. 
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